Oxford Immunotec Global 10-K 28 Mar 19 2018 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2018	Mar. 01, 2019	Jun. 30, 2018
Document Information [Line Items]
Entity Registrant Name	Oxford Immunotec Global PLC
Entity Central Index Key	0001586049
Trading Symbol	oxfd
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Common Stock, Shares Outstanding (in shares)		26,617,311
Entity Public Float			$ 283,039,200
Entity Shell Company	false
Document Type	10-K
Document Period End Date	Dec. 31, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	FY
Amendment Flag	false

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Assets
Cash and cash equivalents	$ 192,844	$ 90,332
Accounts receivable, net	9,158	6,021
Other receivable	4,500
Inventory, net	7,767	7,137
Prepaid expenses and other assets	2,511	2,711
Current assets of discontinued operations		14,281
Total current assets	216,780	120,482
Restricted cash, non-current	100	200
Other receivable	4,500
Property and equipment, net	7,144	2,764
Goodwill	2,483	2,483
Other intangible assets, net	61	1,036
Deferred tax asset	1,052	2,486
Noncurrent assets of discontinued operations		14,785
Total assets	232,120	144,236
Liabilities and shareholders’ equity
Accounts payable	2,801	5,552
Accrued liabilities	10,891	7,807
Settlement liability	4,106	4,342
Deferred income	125	36
Current portion of loans payable	85	78
Current liabilities of discontinued operations		4,630
Total current liabilities	18,008	22,445
Long-term portion of loans payable	106	29,856
Settlement liability		3,894
Other liabilities		364
Noncurrent liabilities of discontinued operations		48
Total liabilities	18,114	56,607
Commitments and contingencies (Notes 3, 9, and 16)
Shareholders' equity:
Ordinary shares, £0.006705 nominal value; 38,978,604 and 36,183,293 shares authorized at December 31, 2018 and 2017, respectively, 26,439,334 and 25,661,634 shares issued and outstanding at December 31, 2018 and 2017, respectively	276	269
Additional paid-in capital	303,015	294,613
Accumulated deficit	(80,762)	(201,541)
Accumulated other comprehensive loss	(8,523)	(5,712)
Total shareholders’ equity	214,006	87,629
Total liabilities and shareholders’ equity	$ 232,120	$ 144,236

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - £ / shares	Dec. 31, 2018	Dec. 31, 2017
Common stock, nominal value (in GBP per share)	£ 0.006705	£ 0.006705
Common stock, shares authorized (in shares)	38,978,604	36,183,293
Common stock, shares issued (in shares)	26,439,334	25,661,634
Common stock, shares outstanding (in shares)	26,439,334	25,661,634

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Revenue:
Revenue	$ 59,753	$ 54,733	$ 46,988
Cost of revenue:
Cost of Goods and Services Sold, Total	16,826	18,470	16,491
Gross profit	42,927	36,263	30,497
Operating expenses:
Research and development	8,122	10,835	9,370
Sales and marketing	26,500	29,053	26,858
General and administrative	25,952	25,450	18,918
Change in fair value of contingent purchase price consideration		(3,475)	(1,208)
Intangible assets impairment charge	879	18,300	1,765
Settlement expense	2,193	10,028
Total operating expenses	63,646	90,191	55,703
Operating loss from continuing operations	(20,719)	(53,928)	(25,206)
Other income (expense):
Interest expense, net	(1,797)	(3,105)	(864)
Loss on extinguishment of debt	(2,105)
Foreign exchange gains (losses)	111	(1,850)	1,364
Other expense	(271)	(209)	(646)
Litigation settlement income		27,500
Loss from continuing operations before income taxes	(24,781)	(31,592)	(25,352)
Income tax benefit (expense) from continuing operations	37,286	(1,634)	3,774
Income (loss) from continuing operations	12,505	(33,226)	(21,578)
Discontinued operations:
Income (loss) from discontinued operations before income taxes	1,727	341	(771)
Gain on disposition	145,982
Income tax expense	(39,435)
Income (loss) from discontinued operations	108,274	341	(771)
Net loss	$ 120,779	$ (32,885)	$ (22,349)
Net income (loss) per ordinary share—basic:
Income (loss) from continuing operations, basic (in dollars per share)	$ 0.48	$ (1.40)	$ (0.97)
Income (loss) from discontinued operations, basic (in dollars per share)	4.17	0.01	(0.03)
Net income (loss), basic (in dollars per share)	4.65	(1.38)	(1)
Net income (loss) per ordinary share—diluted:
Income (loss) from continuing operations, diluted (in dollars per share)	0.47	(1.40)	(0.97)
Income (loss) from discontinued operations, diluted (in dollars per share)	4.10	0.01	(0.03)
Net income (loss), diluted (in dollars per share)	$ 4.58	$ (1.38)	$ (1)
Weighted-average shares used to compute net income (loss) per ordinary share—basic (in shares)	25,982,809	23,757,902	22,353,713
Weighted-average shares used to compute net income (loss) per ordinary share—diluted (in shares)	26,397,875	23,757,902	22,353,713
Product [Member]
Revenue:
Revenue	$ 54,687	$ 48,899	$ 43,070
Cost of revenue:
Cost of Goods and Services Sold, Total	13,668	13,864	13,807
Service [Member]
Revenue:
Revenue	5,066	5,834	3,918
Cost of revenue:
Cost of Goods and Services Sold, Total	$ 3,158	$ 4,606	$ 2,684

Consolidated Statements of Othe

Consolidated Statements of Other Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Net loss	$ 120,779	$ (32,885)	$ (22,349)
Other comprehensive gain (loss), net of taxes:
Foreign currency translation adjustment, net of tax charges / (credits) of $791, $(1,178), and $0, respectively	(2,811)	2,039	(2,474)
Other comprehensive gain (loss), net of taxes	(2,811)	2,039	(2,474)
Total comprehensive income (loss)	$ 117,968	$ (30,846)	$ (24,823)

Consolidated Statements of Shar

Consolidated Statements of Shareholders' Equity - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance at Dec. 31, 2015	$ 243	$ 244,033	$ (146,307)	$ (5,277)	$ 92,692
Exercise of share options		76			76
Share-based compensation expense		5,019			5,019
Other comprehensive loss				(2,474)	(2,474)
Net loss			(22,349)		(22,349)
Balance at Dec. 31, 2016	243	249,128	(168,656)	(7,751)	72,964
Exercise of share options	4	557			561
Share-based compensation expense		5,864			5,864
Other comprehensive loss				2,039	2,039
Net loss			(32,885)		(32,885)
Issuance of shares in secondary offering	22	39,276			39,298
Tax on vesting of restricted share units		(212)			(212)
Balance at Dec. 31, 2017	269	294,613	(201,541)	(5,712)	87,629
Exercise of share options	7	3,234			3,241
Share-based compensation expense		5,551			5,551
Other comprehensive loss				(2,811)	(2,811)
Net loss			120,779		120,779
Tax on vesting of restricted share units		(383)			(383)
Balance at Dec. 31, 2018	$ 276	$ 303,015	$ (80,762)	$ (8,523)	$ 214,006

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Cash flows from operating activities
Net loss	$ 120,779,000	$ (32,885,000)	$ (22,349,000)
Less: Net income (loss) from discontinued operations, net of tax	(108,274,000)	(341,000)	771,000
Net income (loss) from continuing operations	(12,505,000)	33,226,000	21,578,000
Adjustments to reconcile net income (loss) from continuing operations to net cash used in operating activities:
Depreciation and amortization of intangible assets	1,662,000	1,618,000	932,000
Change in fair value of contingent purchase price consideration		(3,475,000)	(1,208,000)
Intangible assets impairment charges	879,000	18,300,000	1,765,000
Accretion and amortization of loan fees	2,408,000	569,000
Share-based compensation expense	4,507,000	5,671,000	4,901,000
Loss (income) on disposal of property and equipment	115,000	298,000
Deferred income taxes	(38,760,000)	1,602,000
Changes in operating assets and liabilities:
Accounts receivable, net	(3,390,000)	(988,000)	(1,642,000)
Inventory, net	(1,015,000)	(1,768,000)	(1,486,000)
Prepaid expenses and other assets	207,000	(454,000)	(3,063,000)
Accounts payable	(10,375,000)	(5,502,000)	(7,326,000)
Accrued liabilities	3,252,000	509,000	3,069,000
Other liabilities, net	(4,209,000)	3,733,000	(36,000)
Deferred income	95,000	(9,000)	(1,639,000)
Net cash used in operating activities from continuing operations	(32,119,000)	(13,122,000)	(27,311,000)
Cash flows from investing activities
Purchases of property and equipment	(5,350,000)	(1,295,000)	(856,000)
Cash paid for acquisitions, net of cash acquired			(27,515,000)
Net cash used in investing activities from continuing operations	(5,350,000)	(1,295,000)	(28,371,000)
Cash flows from financing activities
Proceeds from issuance of ordinary shares		39,298,000
Proceeds from exercise of share options	3,241,000	561,000	76,000
Payments of tax withheld on vesting of restricted share units	(383,000)	(212,000)
Payments on capital lease	(60,000)	(261,000)	(80,000)
Proceeds from term loan, net			29,457,000
Discount on the line of credit			(50,000)
Debt issuance costs			(289,000)
Loss on extinguishment of debt	(2,105,000)
Change in loans payable	(30,000,000)
Net cash (used in) provided by financing activities from continuing operations	(29,307,000)	39,386,000	29,114,000
Net cash flows of continuing operations	(66,776,000)	24,969,000	(26,568,000)
Cash flows from discontinued operations
Net operating cash flows provided by discontinued operations	14,729,000	9,548,000	5,401,000
Net investing cash flows provided by (used in) discontinued operations	156,218,000	(3,734,000)	(1,527,000)
Net financing cash flows used in discontinued operations	(48,000)	(12,000)	(11,000)
Net cash flows of discontinued operations	170,899,000	5,802,000	3,863,000
Effect of exchange rate changes on cash and cash equivalents, including restricted cash	(1,711,000)	451,000	(1,780,000)
Net increase (decrease) in cash and cash equivalents, including restricted cash	102,412,000	31,222,000	(24,485,000)
Cash, cash equivalents, and restricted cash at beginning of year	90,532,000	59,310,000	83,795,000
Cash, cash equivalents, and restricted cash at end of year	192,944,000	90,532,000	59,310,000
Supplemental disclosures
Cash paid for interest	2,656,000	3,123,000	450,000
Cash paid for taxes	$ 76,000	$ 145,000	$ 141,000

Note 1 - Description of Busines

Note 1 - Description of Business and Significant Accounting Policies	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Basis of Presentation and Significant Accounting Policies [Text Block]	1. Description of business The Company is a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for immunology and infectious disease by leveraging the technological, product development, manufacturing, quality, regulatory, and sales and marketing capabilities it has developed over its sixteen TB On November 6, 2018, $170 210 three Discontinued operations The Company reports the results of operations of a business that either has been disposed of or is classified as held for sale, in accordance with Accounting Standards Codification, or ASC, 360, Property, Plant, and Equipment 205, Presentation of Financial Statements As discussed in Note 19, Discontinued operations September 25, 2018, November 6, 2018. Basis of presentation, accounting principles and principles of consolidation The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, or U.S. GAAP, and include the financial statements of Oxford Immunotec Global PLC, a company incorporated in England and Wales and its wholly-owned subsidiaries, collectively referred to as the Company. All intercompany accounts and transactions have been eliminated upon consolidation. Segment reporting The Company operates in one Use of estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and that affect the reported amounts of revenue and expenditures during the reporting periods. Actual results could differ from those estimates and assumptions used. Foreign currency translation The functional currency for Oxford Immunotec Global PLC is the U.S. Dollar. The functional currency for the Company’s operating subsidiaries are the Pound Sterling for Oxford Immunotec Limited, the U.S. Dollar for Oxford Immunotec USA, Inc., Oxford Immunotec Inc. and Immunetics, Inc., or Immunetics, the Yen for Oxford Immunotec K.K., the Yuan for Oxford Immunotec (Shanghai) Medical Device Co. Ltd., the Euro for Boulder Diagnostics Europe GmbH and the Hong Kong Dollar for Oxford Immunotec Asia Limited. Revenue and expenses of foreign operations are translated into U.S. Dollars at the average rates of exchange during the year. Assets and liabilities of foreign operations are translated into U.S. Dollars at year-end rates. The Company reflects resulting foreign currency translation adjustments in accumulated other comprehensive income, which is a component of shareholders’ equity. Realized and unrealized foreign currency transaction gains or losses, arising from exchange rate fluctuations on balances denominated in currencies other than the functional currencies, are included in “Other income (expense)” in the consolidated statements of operations unless the unrealized foreign currency transaction gains or losses relate to intercompany transactions of a long-term investment nature, then they are included in other comprehensive income. Concentration of risks In the year ended December 31, 2018, two 10% March 27% 19% Cash and cash equivalents and restricted cash The Company considers all highly liquid investments purchased with maturities at acquisition of three not Restricted cash relates to collateral for procurement cards issued by a U.S. commercial bank. Cash, cash equivalents, and restricted cash consists of the following: Year ended December 31, (in thousands) 2018 2017 2016 Cash and cash equivalents $ 192,844 $ 90,332 $ 59,110 Restricted cash, non-current 100 200 200 Total cash, cash equivalents, and restricted cash shown in the statement of cash flows $ 192,944 $ 90,532 $ 59,310 Accounts receivable Accounts receivable are primarily amounts due from customers including hospitals, public health departments, commercial testing laboratories, distributors and universities in addition to government programs. Accounts receivable are reported net of an allowance for uncollectible accounts. The process of estimating the collection of accounts receivable involves significant assumptions and judgments. Specifically, the accounts receivable allowance is based on management’s analysis of current and past due accounts, collection experience and other relevant information. The Company’s provision for uncollectible accounts is recorded as a bad debt expense and included in general and administrative expenses. Account balances are written-off against the allowance when it is probable that the receivable will not Inventory Inventory consists of raw materials, work in progress and finished goods. The Company does not not Property and equipment Property and equipment are stated at cost. Property and equipment financed under capital leases are initially recorded at the present value of minimum lease payments at the inception of the lease. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. Property and equipment under capital leases and leasehold improvements are amortized using the straight-line method over the shorter of the lease term or estimated useful life of the asset. Depreciable lives range from three ten three Revenue recognition The Company’s revenues include product and service revenues. Product revenue from diagnostic test kit sales and related accessories is recognized at a point in time based upon contractual rates. Service revenue is recorded based upon contractually established billing rates and recognized upon delivery of test results to the customer. See Note 2 As of December 31, 2018, $9.2 December 31, 2018, no no December 31, 2018. one Revenue expected to be recognized in any future year related to remaining performance obligations is not Taxes assessed by governmental authorities on revenue, including sales and value added taxes, are recorded on a net basis (excluded from revenue) in the consolidated statements of operations. Cost of revenue: cost of product and cost of service Cost of product revenue consists primarily of costs incurred in the production process, including costs of raw materials and components, assembly labor and overhead, quality management, royalties paid under licensing agreements and packaging and delivery costs. Cost of service revenue consists primarily of costs incurred in the operation of the Company’s diagnostic laboratory including labor and overhead, kit costs, quality management, consumables used in the testing process and packaging and delivery costs. Shipping and handling The Company generally bills product customers for shipping and handling and records the customer payments as product revenue. The associated costs are recorded as cost of product sold. The Company does not Impairment of long-lived assets The Company’s long-lived assets, including fixed assets and intangible assets which have a definite life, are evaluated for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may may Business combinations For acquisitions meeting the definition of a business combination, the Company allocates the purchase price, including any contingent consideration, to the assets acquired and the liabilities assumed at their estimated fair values as of the date of the acquisition with any excess of the purchase price paid over the estimated fair value of net assets acquired recorded as goodwill. When determining the fair value of tangible assets acquired, the Company estimates the cost using the most appropriate valuation method with assistance from independent third third Goodwill and indefinite-lived intangible assets Goodwill Goodwill is not fourth may no two first not 50% first not not may not Indefinite-lived intangible assets Indefinite-lived intangible assets are reviewed for impairment at least annually, or when events or changes in the business environment indicate the carrying value may first not 50% first not not may not The determinations as to whether, and, if so, the extent to which, indefinite-lived intangible assets become impaired are highly judgmental and based on significant assumptions regarding the projected future financial condition and operating results, changes in the manner of the use and development of the acquired assets, the Company’s overall business strategy, and regulatory, market and economic environment and trends. Definite-lived intangible assets Intangible assets include technology licenses which are capitalized and amortized over estimated useful lives (generally in the range of five twenty Derivative financial instruments The Company does not The Company reviews the terms of the shares it issues to determine whether there are embedded derivative instruments, including embedded conversion options, which are required to be bifurcated and accounted for separately as derivative financial instruments. In circumstances where the host instrument contains more than one Bifurcated embedded derivatives are initially recorded at fair value and are then revalued at each reporting date with changes in the fair value reported as other income or expense. When equity instruments contain embedded derivative instruments that are to be bifurcated and accounted for as liabilities, the total proceeds received are first Fair value of financial instruments The Company measures certain financial assets and liabilities at fair value based on the price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants. As of December 31, 2018 2017, 3. Fair value measurement Research and development expenses Research and development expenses include all costs associated with the development of the Company’s technology platforms and potential future products including new diagnostic tests that utilize the Company’s technology platforms and are charged to expense as incurred. Research and development expenses include direct costs and an allocation of indirect costs, including amortization, depreciation, rent, supplies, insurance and repairs and maintenance. Share-based compensation The Company accounts for share-based compensation arrangements with employees, officers and directors by recognizing compensation expense based on the grant date fair value of share-based transactions in the consolidated financial statements. Share-based compensation for options is based on the fair value of the underlying option calculated using the Black-Scholes option-pricing model on the date of grant for share options and recognized as expense on a straight-line basis over the requisite service period. Determining the appropriate fair value model and related assumptions requires judgment, including estimating share price volatility, expected term and forfeiture rates. The expected volatility rates are estimated based on the Company’s actual volatility and the actual volatility of comparable public companies over a historical period equal in length to the expected term. The expected terms represent the average time that options are expected to be outstanding based on the midpoint between the vesting date and the end of the contractual term of the award. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company has not not Certain employees have been granted restricted share units, or RSUs, and restricted shares. The fair value of RSUs and restricted shares are calculated based on the closing sale price of the Company’s ordinary shares on the date of grant. The cumulative expense recognized for share-based transactions at each reporting date until the vesting date reflects the extent to which the vesting period has expired and the Company’s best estimate of the number of equity instruments that will ultimately vest. The charge or credit for a period represents the movement in cumulative expense recognized as of the beginning and end of that period. No not Where the terms of an equity award are modified, the minimum expense recognized is the expense as if the terms had not Where a share-based compensation award is cancelled, it is treated as if it had vested on the date of cancellation, and any expense not Upon exercise, share options are redeemed for newly issued ordinary shares. Income taxes The Company accounts for income taxes under the asset and liability method, which requires, among other things, that deferred income taxes be provided for temporary differences between the tax basis of the Company’s assets and liabilities and its financial statement reported amounts. In addition, deferred tax assets are recorded for the future benefit of utilizing net operating losses and research and development credit carryforwards. A valuation allowance is established when necessary to reduce deferred tax assets to the amount expected to be realized. The Company adheres to the accounting guidance for uncertainties in income taxes, which prescribes a recognition threshold and measurement process for recording in the financial statements uncertain tax positions taken, or expected to be taken, in a tax return. The Company accrues for the estimated amount of taxes for uncertain tax positions if it is more likely than not not 50% Basic and diluted net income (loss) per ordinary share Basic income (loss) per ordinary share are calculated by dividing the net income (loss) by the weighted-average number of ordinary shares outstanding during the period. Diluted income per ordinary share is calculated by dividing net income by the weighted-average number of ordinary shares outstanding during the period plus the dilutive effect of outstanding instruments such as share options, RSUs and restricted shares. Diluted loss per ordinary share is the same as basic loss per ordinary share, as the effect of utilizing the fully diluted share count including share options, RSUs and restricted shares would reduce the net loss per ordinary share. Recently Adopted Accounting Pronouncements In May 2014, 2014 09, Revenue from Contracts with Customers 2014 09, 2014 09, 2014 09 2014 09 January 1, 2018, 2014 09 not December 31, 2018. 2014 09 2. Revenue In August 2016, 2016 15, Classification of Certain Cash Receipts and Cash Payments 2016 15. 2016 15 2016 15 January 1, 2018. 2016 15 not In October 2016, 2016 16, Income Taxes 2016 16. 2016 16 January 1, 2018. 2016 16 not In November 2016, 2016 18, Statement of Cash Flows (Topic 230 2016 18. 2016 18 2016 18 January 1, 2018. 2016 18 not In January 2017, 2017 01, Business Combinations 2017 01. 2017 01 2017 01 January 1, 2018. 2017 01 not In May 2017, 2017 09, Scope of Modification Accounting 2017 09. 2017 09 2017 09 January 1, 2018. 2017 09 not Recently Issued Accounting Pronouncements In February 2016, 2016 02, Leases 2016 02. 2016 02 12 2016 02 2016 02, January 1, 2019 2016 02, 12 not 2016 02, $7.7 $8.6 no first 2019, In June 2016, 2016 13, Financial Instruments-Credit Losses 2016 13. 2016 13 2016 13, December 15, 2019. December 15, 2018. not 2016 13 In January 2017, 2017 04, Intangibles – Goodwill and Other 2017 04. 2017 04 2 2017 04 December 15, 2019. 2017 04. In June 2018, 2018 07, Improvements to Nonemployee Share-Based Payment Accounting 2018 07. 2018 07 2018 07 December 15, 2018, 2018 07.

Note 2 - Revenue

Note 2 - Revenue	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	2. On January 1, 2018, 606, Revenue from Contracts with Customers, 606, 606 10 10 4. five 606 1 2 3 4 5 606 not not December 31, 2018. The Company’s prior year revenues have been recast to present the U.S. Laboratory Services Business as a discontinued operation. For further information on these changes, refer to Note 19. Discontinued operations. The following tables present the Company’s revenues disaggregated by type: Year ended December 31, (in thousands) 2018 2017 2016 Revenue Product $ 54,687 $ 48,899 $ 43,070 Service 5,066 5,834 3,918 Total revenue $ 59,753 $ 54,733 $ 46,988 The following tables reflect revenue by geography (United States, Europe and rest of world, or Europe and ROW, and Asia): Year ended December 31, (in thousands, except percentages) 2018 2017 2016 Revenue United States $ 16,442 28 % $ 15,720 29 % $ 10,372 22 % Europe and ROW 9,153 15 % 8,136 15 % 6,988 15 % Asia 34,158 57 % 30,877 56 % 29,628 63 % Total revenue $ 59,753 100 % $ 54,733 100 % $ 46,988 100 %

Note 3 - Fair Value Measurement

Note 3 - Fair Value Measurement	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Fair Value Disclosures [Text Block]	3. As a basis for determining the fair value of certain of the Company’s financial instruments, the Company utilizes a three Level 1—Observable Level 2—Observable 1 not Level 3—Unobservable no This hierarchy requires the Company to use observable market data, when available, and to minimize the use of unobservable inputs when determining fair value. The carrying amount of certain of the Company’s financial instruments, including cash, accounts receivable, prepaid expenses and other assets, accounts payable, and accrued liabilities approximate fair value due to their short term nature. Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company’s assessment of the significance of a particular input to the entire fair value measurement requires management to make judgments and consider factors specific to the asset or liability. The Company had a term loan outstanding under an agreement with MidCap Financial Trust, or MidCap, at December 31, 2017. , 2 November 6, 2018, $32.3 $2.3 Note 9. p ayable

Note 4 - Accounts Receivable, N

Note 4 - Accounts Receivable, Net	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Financing Receivables [Text Block]	4. Accounts receivable, net, consisted of the following as of: December 31, (in thousands) 2018 2017 Accounts receivable $ 9,246 $ 6,021 Less allowance for uncollectible accounts receivable (88 ) — Accounts receivable, net $ 9,158 $ 6,021 Activity for the allowance for uncollectible accounts receivable is as follows: December 31, (in thousands) 2018 2017 2016 Balance at beginning of period $ — $ — $ — Provision for bad debt expense (88 ) — — Write-off — — — Balance at end of period $ (88 ) $ — $ —

Note 5 - Inventory, Net

Note 5 - Inventory, Net	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Inventory Disclosure [Text Block]	5. Inventory consisted of the following as of: December 31, (in thousands) 2018 2017 Raw materials $ 6,169 $ 6,927 Work in progress 190 179 Finished goods 1,408 31 Inventory $ 7,767 $ 7,137

Note 6 - Property and Equipment

Note 6 - Property and Equipment, Net	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	6. Property and equipment, net consists of the following as of: December 31, (in thousands) 2018 2017 Laboratory equipment $ 2,951 $ 2,493 Leasehold improvements 5,663 2,766 Office equipment, furniture and fixtures 3,019 2,205 Software 1,626 756 Construction in progress — 94 Property and equipment 13,259 8,314 Less accumulated depreciation (6,115 ) (5,550 ) Property and equipment, net $ 7,144 $ 2,764 For the years ended December 31, 2018, 2017 2016, $1.6 $1.4 $0.9 Depreciable lives range from three ten three For the years ended December 31, 2018 2017, no

Note 7 - Goodwill and Intangibl

Note 7 - Goodwill and Intangible Assets	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Goodwill and Intangible Assets Disclosure [Text Block]	7. The Company has one 19. Discontinued operations 350 20 35 51, $1.5 third 2018, $2.5 December 31, 2018 2017. Acquired intangible assets consisted of the following as of December 31, 2018 2017 As of December 31, 2018 Amortization period (years) Gross carrying amount Accumulated Amortization Net carrying amount Licenses 5 - 10 $ 652 $ 591 $ 61 Total $ 652 $ 591 $ 61 As of December 31, 2017 Amortization period (years) Gross carrying amount Accumulated Amortization Net carrying amount Immunetics technology – clinical 15 $ 883 $ 72 $ 811 Immunetics customer relationships 5 - 11 130 14 116 Immunetics trade name 5 30 8 22 Other 5 - 10 692 605 87 Total $ 1,735 $ 699 $ 1,036 In conjunction with the Transaction, the net carrying amount of definite-lived intangible assets recorded in the acquisition of Imugen were disposed of and netted into the gain on sale. The weighted average amortization period of our definite-lived intangible assets is 9.7 December 31, 2018, 2017 2016 $93,000, $206,000 $71,000, $22,000 2019 2020 $17,000 2021. The acquisition of Immunetics was accounted for under the acquisition method of accounting and the purchase price allocation was provisionally prepared during the fourth 2016. second 2017, ● the fair value of the acquired inventory decreased by $45,000 $22,500 $22,500 ● the fair value of the acquired customer relationships decreased by $50,000 ● the fair value of the Immunetics trade name decreased by $130,000 ● a $58,000 The impact on the consolidated statement of operations as of December 31, 2017 $44,000 $26,000 $58,000 During the fourth 2016, $1.4 not In the third 2017, Babesia microti $11.1 2016 ● $9.2 ● $1.1 ● $701,000 In mid- February 2018, fourth 2017 Babesia microti $7.2 ● $7.0 ● $166,000 ● $98,000 Impairment review Immunetics definite-lived intangible assets The Company reviews the carrying value of its long-lived assets, including other intangible assets, for impairment whenever events or changes in circumstances indicate that the carrying value of an asset or asset group may not November 6, 2018, $170 19. Discontinued operations). $879,000 fourth 2018. Goodwill Goodwill is not fourth may no two no fourth 2018.

Note 8 - Accrued Liabilities

Note 8 - Accrued Liabilities	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	8. Accrued liabilities consist of the following as of: December 31, (in thousands) 2018 2017 Employee related expenses $ 5,536 $ 4,317 Corporate tax 1,616 — Royalties 1,354 1,419 Other accrued liabilities 2,385 2,071 Total accrued liabilities $ 10,891 $ 7,807

Note 9 - Loans Payable

Note 9 - Loans Payable	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Debt Disclosure [Text Block]	9. In June 2013, 14,500 $582,000 80% 840, Leases December 31, 2018, $84,000 $75,000 December 31, 2017, $77,000 $159,000 On October 4, 2016, $40 $30 five 7.60% first 24 48 $10 five 4.45%. 0.50% $10 $60 If the credit facility was terminated prior to the end of the term, the Company was to pay to the lenders a fee as compensation for the costs of being prepared to make funds available to the Company throughout the term equal to an amount determined by multiplying the revolving line of credit commitment amount by 3.0% first 2.0% second 1.0% third 6% 6.0% 6% In connection with the sale of the U.S. Laboratory Services Business to Quest pursuant to a Limited Liability Company Interest Purchase Agreement on November 6, 2018, $32.3 $2.3 $2.1 As of December 31, 2017, $30 The Company never borrowed under the revolving line of credit.

Note 10 - Share Capital

Note 10 - Share Capital	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	10. During the twelve 2018, 694,322 83,378 2017, 500,182 26,021 36,183,293 26,439,334 25,661,634 December 31, 2018 2017, On August 14, 2017, 2,500,000 £0.006705 $16.05 $39.3 August 18, 2017.

Note 11 - Share Option and Equi

Note 11 - Share Option and Equity Incentive Plans	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	11. The Company has issued share options since 2003, 2014 2015 two 2008 2013 2013 2013 no 2008 In November 2013, 2013 2013 2,684,563 January 1 st January 1, 2023 4% December 31 st may no 2013 April 2017 2,684,563, 2013 December 31, 2018, 1,712,132 2013 Under both the 2008 2013 2013 ten 2015, 0% second first 2008 second first second 2013 2015, four 40% second 30% third 30% fourth The fair value of the options was estimated at the grant date using the Black-Scholes option pricing model, taking into account the terms and conditions upon which options are granted. The fair value of the options is amortized on a straight-line basis over the requisite service period of the awards. The weighted-average grant date fair value per share relating to share options granted under the Plans during the years ended December 31, 2018, 2017 2016 $6.15, $6.31 $4.53, The fair value of each option granted under the Plans has been calculated on the date of grant using the following assumptions: 2018 2017 2016 Expected dividend yield (%) — — — Expected volatility (%) 43.70 43.59 43.70 Risk-free interest rate (%) 2.70 1.98 1.53 Expected life of option (years) 6.25 6.20 6.16 Weighted-average share price ($) 13.37 14.06 10.29 Weighted-average exercise price ($) 4.67 14.06 10.29 Model used Black-Scholes Model Black-Scholes Model Black-Scholes Model Expected dividend yield: not not Expected volatility: November 2013, not first 75% 25% second 50% 50% 25% Risk-free interest rate: Expected life of options (in years): November 2013, not Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from estimates. The Company estimates forfeitures based on historical termination behavior. For the years ended December 31, 2018, 2017 2016, 5% The following table illustrates the number of ordinary shares and weighted-average exercise prices, or WAEP, of, and movements in, share options during the year: Number of ordinary shares WAEP Outstanding as of January 1, 2018 3,104,613 $ 11.62 Granted 796,264 13.37 Exercised (694,322 ) 4.67 Forfeited (643,386 ) 14.31 Outstanding as of December 31, 2018 2,563,169 13.37 Vested or expected to vest as of December 31, 2018 2,494,307 $ 13.37 Exercisable as of December 31, 2018 1,401,639 $ 13.47 The following table illustrates the number of restricted shares and RSUs, and weighted-average fair value, or WAFV, of, and movements in, restricted shares and RSUs during the year: Number of ordinary shares WAFV Unvested balance as of January 1, 2018 418,518 $ 14.93 Granted 166,008 13.37 Cancelled (112,694 ) 13.09 Vested (170,878 ) 16.98 Unvested balance as of December 31, 2018 300,954 13.88 As of December 31, 2018, $5.2 $3.0 2.4 2.6 The aggregate intrinsic value of all share options outstanding under the Plans as of December 31, 2018 2017 $2.8 $10.7 December 31, 2018 2017 $2.4 $8.8 During the years ended December 31, 2018, 2017 2016, 694,322, 500,182 85,943 $3.2 2018, $561,000 2017 $76,000 2016. December 31, 2018, 2017 2016 $6.7 $7.2 $1.0 A summary of the activity of the Company’s unvested share options is as follows: Number of shares Weighted- average grant date fair value Balance as of December 31, 2017 1,479,293 $ 5.83 Granted 796,264 6.15 Vested (651,787 ) 5.59 Forfeited (462,240 ) 6.56 Balance as of December 31, 2018 1,161,530 6.06 The total fair value of shares vested for the years ended December 31, 2018, 2017 2016 $3.7 $3.1 $2.9 The impact on the Company’s results of continuing and discontinued operations from share-based compensation for the years ended December 31, 2018, 2017 2016, (in thousands) 2018 2017 2016 Cost of revenue $ 182 $ 168 $ 52 Research and development 758 654 497 Sales and marketing 965 1,844 1,671 General and administrative 2,602 3,005 2,681 Total continuing operations 4,507 5,671 4,901 Discontinued operations 1,044 193 118 Total share-based compensation $ 5,551 $ 5,864 $ 5,019 On September 10, 2018, 35 September 25, 2018, no 120,000 28,100 For the year ended December 31, 2018, $3.6 $2.0 December 31, 2017, $3.6 $2.2 December 31, 2016, $3.2 $1.8

Note 12 - Net Income (Loss) Per

Note 12 - Net Income (Loss) Per Ordinary Share	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Earnings Per Share [Text Block]	12. The following table provides a reconciliation of the numerator and denominator used in computing basic and diluted net income (loss) per share: Year ended December 31, ($ in thousands) 2018 2017 2016 Numerator: Income (loss) from continuing operations $ 12,505 $ (33,226 ) $ (21,578 ) Income (loss) from discontinued operations 108,274 341 (771 ) Net income (loss) $ 120,779 $ (32,885 ) $ (22,349 ) Denominator: Weighted-average ordinary shares outstanding-basic 25,982,809 23,757,902 22,353,713 Dilutive effect of ordinary share equivalents resulting from ordinary share options, unvested restricted shares and RSUs 415,066 — — Weighted-average ordinary shares outstanding-diluted 26,397,875 23,757,902 22,353,713 The following numbers of outstanding ordinary share options, restricted shares and RSUs were excluded from the computation of diluted net loss per share for the periods with a net loss because their effect would have been anti-dilutive: Year ended December 31, 2018 2017 2016 Options to purchase ordinary shares — 878,242 1,065,655 Unvested restricted shares and RSUs — 418,518 329,465

Note 13 - Income Taxes

Note 13 - Income Taxes	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Income Tax Disclosure [Text Block]	13. The components of loss from continuing operations before income taxes are as follows for the years ended December 31: (in thousands) 2018 2017 2016 Domestic (United Kingdom) $ 12,623 $ 18,171 $ (730 ) Foreign (United States) (37,404 ) (49,763 ) (24,622 ) Loss from continuing operations before income taxes $ (24,781 ) $ (31,592 ) $ (25,352 ) The components for the income tax (expense) benefit from continuing operations are as follows for the years ended December 31: (in thousands) 2018 2017 2016 Current: Federal $ — $ — $ — U.K. (532 ) — — Japan (45 ) (14 ) (85 ) China (13 ) (39 ) (12 ) State — (46 ) (51 ) Total current provision (590 ) (99 ) (148 ) Deferred: Federal 30,665 — 752 U.K. (1,343 ) (1,535 ) 2,630 State 8,554 — 540 Total deferred benefit (expense) 37,876 (1,535 ) 3,922 Income tax benefit (expense) $ 37,286 $ (1,634 ) $ 3,774 Intraperiod tax allocation rules require the Company to allocate the provision for income taxes between continuing operations and other categories of earnings, such as discontinued operations and other comprehensive income. In periods in which the Company has a year-to-date pre-tax loss from continuing operations and pre-tax income in other categories of earnings, such as discontinued operations, we must allocate the tax provision to the other categories of earnings. As a result, the Company has recorded a tax expense of approximately $39.4 The Company’s effective income tax rate differs from the statutory domestic (United Kingdom) income tax rate as follows for the years ended December 31: 2018 2017 2016 Income tax rate 19.0 % 19.3 % 20.0 % U.K. research and development credit 1.8 1.5 1.9 Effect of U.S. tax reform – Federal tax rate change — (69.2 ) — Permanent items 1.0 5.9 (1.9 ) Prior period adjustments (5.2 ) — — State taxes 9.2 9.6 4.9 Other 2.0 4.6 (1.5 ) Effect of foreign tax rate differential 2.9 28.0 13.1 Uncertain tax positions (1.7 ) — — Valuation allowance 121.5 (5.0 ) (21.6 ) Effective income tax rate 150.5 % (5.3 )% 14.9 % The Company is headquartered in the United Kingdom and the statutory U.K. corporate tax rate for the years ended December 31, 2018, 2017 2016 19.0%, 19.3% 20.0%, December 31, 2018, 2017 2016 21%, 34% 34%, 2015 2018. no 2014 2014 The United Kingdom’s Summer Finance Bill, which was enacted on September 15, 2016, 19% April 1, 2017 17% April 1, 2020. 17%, Deferred income taxes reflect the net tax effect of temporary differences between the carrying amount of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s deferred tax assets and deferred tax liabilities are as follows for the years ended December 31: (in thousands) 2018 2017 Deferred tax assets: U.S. federal net operating losses $ 11,478 $ 33,713 State net operating loss (net of federal) 2,865 8,450 U.S. federal research and development credit 849 587 U.K. net operating loss 496 1,894 Share options 1,724 2,611 Accrued liabilities 1,052 393 Intangible assets — 2,392 State credits 512 377 Other 136 167 Total deferred tax assets 19,112 50,584 Valuation allowance (17,991 ) (48,098 ) Total deferred tax assets $ 1,121 $ 2,486 Deferred tax liabilities: Other assets $ (69 ) $ — Total deferred tax liabilities $ (69 ) $ — On December 22, 2017, 2017, 34% 21% January 1, 2018. 21% $21.4 not not 2017 2018 For the years ended December 31, 2018 2017, $2.9 $11.1 December 31, 2018 2017 $54.7 $160.5 December 31, 2018 2017 $50.3 $154.9 The U.S. federal and state net operating loss carryforwards begin to expire in 2019 2019, For the year ended December 31, 2018, not $1.1 not not’ The following table reflects the rollforward of the Company’s valuation allowance: (in thousands) 2018 2017 2016 Beginning of year (January 1) $ 48,098 $ 46,473 $ 43,076 (Decrease) increase in valuation allowance (30,107 ) 1,625 3,397 End of year (December 31) $ 17,991 $ 48,098 $ 46,473 Interest and penalties related to uncertain tax positions are recorded in tax expense and totaled $37,000, $0 $0 December 31, 2018, 2017 2016, $37,000 $0 December 31, 2018 2017, $409,000 $0 December 31, 2018 2017, The Company did not December 31, 2017. The aggregate changes in the balance of gross uncertain tax positions, which excludes interest and penalties, for the year ended December 31, 2018 Balance at December 31, 2017 $ — Settlement/decreases related to tax positions taken during prior years — Increases related to tax positions taken during prior years 372 Increases related to tax positions taken during the current year — Balance at December 31, 2018 $ 372 The Company generates research and development credits in the United Kingdom which are refundable if a current year loss is incurred. In the United Kingdom for the year ended December 31, 2018, no The SEC staff issued SAB 118 December 31, 2017, December 31, 2018 no

Note 14 - Intellectual Property

Note 14 - Intellectual Property - License Agreements	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
License Agreements [Text Block]	14. The Company entered into three TB November 2013, one On June 30, 2017, no The Company’s existing license agreements related to its T-SPOT. TB December 31, 2018 16. Commitments and contingencies The Company incurs royalties under each existing license agreement, has incurred royalties under the Oxford Innovation license agreement, and will incur continuing payment obligations to Oxford Innovation that are treated as royalties in these financial statements, based on its product and service revenue. The aggregate royalty expense relating to the three $1.1 $2.8 $5.2 December 31, 2018, 2017 2016, $83,000, $80,000 $161,000 December 31, 2018, 2017 2016, December 31, 2018, 2017 2016, 2%, 5% 11%,

Note 15 - Employee Benefit Plan

Note 15 - Employee Benefit Plans	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Compensation and Employee Benefit Plans, Other than Share-based Compensation [Text Block]	15. In the United States, the Company has adopted a defined contribution plan (the U.S. Plan) which qualifies under Section 401 21 January 1, 2008. may July 1, 2016 $314,000, $277,000 $126,000 December 31, 2018, 2017 2016, In the United Kingdom, the Company has adopted a defined contribution plan (the U.K. Plan) which qualifies under the rules established by HM Revenue & Customs. The U.K. Plan allows all U.K. employees to contribute a minimum of 5% no 5% $685,000 December 31, 2018, $613,000 December 31, 2017 $636,000 December 31, 2016.

Note 16 - Commitments and Conti

Note 16 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	16. Operating leases At December 31, 2018, seven 2019 2033. June 11, 2019 June 18, 2033. March 1, 2013, five August 2015, two October 31, 2020. 7,600 22,100 $36,000 $12,000 2016, $39,000 one five In connection with the sale of our U.S. Laboratory Services Business to Quest, we entered into a sublease with Quest for approximately 9,000 November 2020. $17,000 In June 2018, June 2033 $39,000 $79,000 third 2018. Future minimum lease payments required under the non-cancelable operating leases in effect as of December 31, 2018 (in thousands) December 31, 2019 $ 2,024 2020 1,848 2021 972 2022 855 2023 855 Thereafter 7,558 Total minimum lease payments $ 14,112 Rent expense is calculated on a straight-line basis over the term of the lease. Rent expense recognized under operating leases totaled $2.3 $1.6 $1.1 December 31, 2018, 2017 2016, Purchase commitments The Company has license agreements with third 14. Intellectual property—license agreements Future minimum payments required under license agreements and supplier purchase obligations in effect as of December 31, 2018 (in thousands) License agreements Supplier purchase obligations Total 2019 $ 262 $ 8,723 $ 8,985 2020 134 — 134 2021 59 — 59 2022 59 — 59 2023 59 — 59 Thereafter 695 — 695 Total minimum payments $ 1,268 $ 8,723 $ 9,991 Legal contingencies The Company is subject to claims and assessments from time to time in the ordinary course of business. The Company does not Indemnification In the normal course of business, the Company enters into contracts and agreements that contain a variety of representations and warranties and provide for general indemnification. The Company’s exposure under these agreements is unknown because it involves claims that may not not may In accordance with its articles of association, the Company has indemnification obligations to its officers and directors for certain events or occurrences, subject to certain limits, while they are serving at the Company’s request in such capacity. There have been no may

Note 17 - Geographic Revenue an

Note 17 - Geographic Revenue and Long-lived Assets Distribution	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	17. The Company is domiciled in the United Kingdom and operates in three December 31, 2018, 2017 2016 December 31, 2018 2017. Revenue Long-lived assets Years ended December 31, As of December 31, (in thousands) 2018 2017 2016 2018 2017 United States $ 16,442 $ 15,720 $ 10,372 $ 1,685 $ 1,071 United Kingdom 3,626 3,041 2,620 5,248 1,487 Europe and ROW (excluding United Kingdom) 5,527 5,095 4,368 101 132 Europe and ROW 9,153 8,136 6,988 5,349 1,619 Asia 34,158 30,877 29,628 110 74 Total $ 59,753 $ 54,733 $ 46,988 $ 7,144 $ 2,764 China represented approximately 48%, 46% 44% 2018, 2017 2016, 50%, 51% 55% 2018, 2017 2016,

Note 18 - Acquisition Activity

Note 18 - Acquisition Activity	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Business Combination Disclosure [Text Block]	18. Imugen, Inc. On July 1, 2016, The consideration for the acquisition of Imugen consisted of $22.2 8 September 9, 2016. The acquisition of Imugen was accounted for under the acquisition method of accounting and the purchase price allocation was provisionally prepared during the third 2016. fourth 2016. The table below summarizes the purchase price of the Imugen acquisition and the fair value of identified assets acquired at the acquisition date (in thousands): Assets acquired: Property and equipment $ 655 In-process research and development 9,200 Technology - clinical 5,100 Customer relationships 2,700 Trademarks / trade names 1,900 Total assets acquired 19,555 Add: Goodwill 2,645 Total consideration transferred $ 22,200 On the date of the acquisition, the fair value of acquired intangible assets was determined to be $18.9 not 22%. 3 Goodwill of approximately $2.6 not 15 During the year ended December 31, 2016, $475,000 Actual results of operations for the year ended December 31, 2016 $7.0 $730,000, not See Note 7. Goodwill and intangible assets With the exception of the blood donor screening business, the bulk of the remaining assets acquired from Imugen were sold to Quest in the Transaction. Immunetics, Inc. On October 12, 2016, Total consideration consisted of $6.0 $6.0 three The acquisition of Immunetics was accounted for under the acquisition method of accounting and the purchase price allocation was provisionally prepared during the fourth 2016. second 2017, ● the fair value of the acquired inventory decreased by $45,000 $22,500 $22,500 ● the fair value of the acquired customer relationships decreased by $50,000 ● the fair value of the Immunetics trade name decreased by $130,000 ● goodwill decreased by $58,000 The impact on the consolidated statement of operations for the year ended December 31, 2016 $44,000 $26,000 $58,000 The Company paid approximately $655,000 December 31, 2016. Total consideration was (in thousands): Cash consideration $ 6,000 Estimated fair value of contingent consideration 3,444 Total consideration transferred $ 9,444 The table below summarizes the final purchase price allocation for the Immunetics acquisition (in thousands): Assets acquired: Cash $ 285 Accounts receivable, net 347 Inventory, net 375 Prepaid expenses and other assets 199 Property and equipment 787 In-process research and development 6,970 Customer relationships 350 Trade name 160 Technology – clinical 883 Grants 50 Total assets acquired 10,406 Liabilities assumed: Accounts payable (319 ) Accrued liabilities (739 ) Other liabilities (1,226 ) Total liabilities assumed (2,284 ) Net assets acquired 8,122 Add: Goodwill 1,322 Total consideration transferred $ 9,444 On the date of the acquisition, the fair value of acquired intangible assets was determined to be $8.4 not 21.6% 60.2%, 3 Actual results of operations for the year ended December 31, 2016 $392,000 $813,000, not Goodwill of approximately $1.3 not no December 31, 2018 no December 31, 2018. not See Note 7. Goodwill and intangible assets The remaining definite-lived intangible assets recorded in the acquisition of Immunetics were written-off in the fourth 2018,

Note 19 - Discontinued Operatio

Note 19 - Discontinued Operations	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]	19. As previously disclosed, on September 25, 2018, $170 $32.3 $2.3 9. Loans payable As contemplated in the Purchase Agreement, Oxford Immunotec USA, Inc., a Delaware corporation and a newly formed wholly owned subsidiary of Oxford Limited (“Oxford USA”), joined the Purchase Agreement by way of a Joinder Agreement dated October 1, 2018. The Transaction was consummated in accordance with the terms and conditions of the Purchase Agreement on November 6, 2018, The U.S. Laboratory Services Business at the time of the sale had a carrying value of $27.9 $146.0 December 31, 2018. Additionally, pursuant to the terms of the Purchase Agreement, the parties entered into certain ancillary agreements as of the Closing Date, including: (i) a transitional services agreement, or TSA, that will continue, unless otherwise terminated, until each service included in the TSA has been completed, (ii) a technology license agreement that will remain in effect until the date of expiration or lapse of the last to expire or lapse Blood Stability Patent and (iii) a long-term supply agreement, or the Supply Agreement, pursuant to which Oxford USA agreed to sell, and Quest agreed to purchase, T-SPOT. TB seven In conjunction with the Purchase Agreement, Quest has agreed to purchase kits and accessories from the Company for an initial period of seven During the year ended December 31, 2018 2017, $8.0 $8.4 Transaction expenses of $3.3 December 31, 2018. The table below provides a reconciliation of the carrying amounts of major classes of assets and liabilities of the discontinued operations that are disclosed in these notes to the consolidated financial statements to the total assets and liabilities of the disposal group classified as assets and liabilities of discontinued operations that are presented separately in the consolidated balance sheets. The assets and liabilities of the disposal group presented as assets and liabilities of discontinued operations have been reclassified in the Company’s consolidated balance sheet as of December 31, 2017. December 31, (in thousands) 2017 Carrying amounts of major classes of assets included as part of discontinued operations: Accounts receivable, net $ 10,961 Inventory, net 3,005 Prepaid expenses and other assets 315 Total major classes of current assets of the discontinued operations 14,281 Property and equipment, net 6,303 Goodwill 1,484 Other intangible assets, net 6,813 Other assets 185 Total major classes of noncurrent assets of the discontinued operations 14,785 Total assets of the disposal group classified as assets of discontinued operations in the consolidated balance sheets $ 29,066 Carrying amounts of major classes of liabilities included as part of discontinued operations: Current liabilities: Accounts payable $ 1,290 Accrued liabilities 3,326 Other liabilities 14 Total major classes of current liabilities of the discontinued operations 4,630 Total major classes of noncurrent liabilities of the discontinued operations 48 Total liabilities of the disposal group classified as liabilities of discontinued operations in the consolidated balance sheets $ 4,678 The following table presents the results of discontinued operations: Year Ended December 31, (in thousands) 2018 2017 2016 Major classes of line items constituting income (loss) from discontinued operations before income taxes: Service revenue $ 53,325 $ 56,700 $ 45,705 Cost of service revenue 34,662 36,613 29,596 Gross profit 18,663 20,087 16,109 Research and development 5,751 5,866 4,542 Sales and marketing 7,592 8,963 8,106 General and administrative 3,593 4,917 4,232 Income (loss) from discontinued operations before income taxes 1,727 341 (771 ) Gain on disposition 145,982 — — Income tax expense (39,435 ) — — Income (loss) from discontinued operations $ 108,274 $ 341 $ (771 )

Note 20 - Restructuring

Note 20 - Restructuring	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Restructuring and Related Activities Disclosure [Text Block]	20. During the third 2017, 15 fourth 2017 $169,000 $13,000 A summary of these charges and payments made to date are included in the below table. Accrued restructuring costs at December 31, 2018 2017 (in thousands) Severance Balance at December 31, 2016 $ — Charge for restructuring 182 Payments during 2017 (108 ) Balance at December 31, 2017 74 Payments during 2018 (70 ) Balance at December 31, 2018 $ 4 In addition to the items listed above, the Company recorded charges in the third 2017 $28,000 no $26,000

Note 21 - Settlement Expense

Note 21 - Settlement Expense	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Settlement Expense [Text Block]	21. On June 18, 2018, October 12, 2016. no On June 30, 2017,

Note 22 - Litigation Settlement

Note 22 - Litigation Settlement Income	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Settlement Income [Text Block]	22. In December 2017, one $27.5

Note 23 - Subsequent Events

Note 23 - Subsequent Events	12 Months Ended
	Dec. 31, 2018
Notes to Financial Statements
Subsequent Events [Text Block]	23. Effective March 5, 2019, 2013

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2018
Accounting Policies [Abstract]
Discontinued Operations, Policy [Policy Text Block]	Discontinued operations The Company reports the results of operations of a business that either has been disposed of or is classified as held for sale, in accordance with Accounting Standards Codification, or ASC, 360, Property, Plant, and Equipment 205, Presentation of Financial Statements As discussed in Note 19, Discontinued operations September 25, 2018, November 6, 2018.
Basis of Accounting, Policy [Policy Text Block]	Basis of presentation, accounting principles and principles of consolidation The accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, or U.S. GAAP, and include the financial statements of Oxford Immunotec Global PLC, a company incorporated in England and Wales and its wholly-owned subsidiaries, collectively referred to as the Company. All intercompany accounts and transactions have been eliminated upon consolidation.
Segment Reporting, Policy [Policy Text Block]	Segment reporting The Company operates in one
Use of Estimates, Policy [Policy Text Block]	Use of estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and that affect the reported amounts of revenue and expenditures during the reporting periods. Actual results could differ from those estimates and assumptions used.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign currency translation The functional currency for Oxford Immunotec Global PLC is the U.S. Dollar. The functional currency for the Company’s operating subsidiaries are the Pound Sterling for Oxford Immunotec Limited, the U.S. Dollar for Oxford Immunotec USA, Inc., Oxford Immunotec Inc. and Immunetics, Inc., or Immunetics, the Yen for Oxford Immunotec K.K., the Yuan for Oxford Immunotec (Shanghai) Medical Device Co. Ltd., the Euro for Boulder Diagnostics Europe GmbH and the Hong Kong Dollar for Oxford Immunotec Asia Limited. Revenue and expenses of foreign operations are translated into U.S. Dollars at the average rates of exchange during the year. Assets and liabilities of foreign operations are translated into U.S. Dollars at year-end rates. The Company reflects resulting foreign currency translation adjustments in accumulated other comprehensive income, which is a component of shareholders’ equity. Realized and unrealized foreign currency transaction gains or losses, arising from exchange rate fluctuations on balances denominated in currencies other than the functional currencies, are included in “Other income (expense)” in the consolidated statements of operations unless the unrealized foreign currency transaction gains or losses relate to intercompany transactions of a long-term investment nature, then they are included in other comprehensive income.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of risks In the year ended December 31, 2018, two 10% March 27% 19%
Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and cash equivalents and restricted cash The Company considers all highly liquid investments purchased with maturities at acquisition of three not Restricted cash relates to collateral for procurement cards issued by a U.S. commercial bank. Cash, cash equivalents, and restricted cash consists of the following: Year ended December 31, (in thousands) 2018 2017 2016 Cash and cash equivalents $ 192,844 $ 90,332 $ 59,110 Restricted cash, non-current 100 200 200 Total cash, cash equivalents, and restricted cash shown in the statement of cash flows $ 192,944 $ 90,532 $ 59,310
Loans and Leases Receivable, Allowance for Loan Losses Policy [Policy Text Block]	Accounts receivable Accounts receivable are primarily amounts due from customers including hospitals, public health departments, commercial testing laboratories, distributors and universities in addition to government programs. Accounts receivable are reported net of an allowance for uncollectible accounts. The process of estimating the collection of accounts receivable involves significant assumptions and judgments. Specifically, the accounts receivable allowance is based on management’s analysis of current and past due accounts, collection experience and other relevant information. The Company’s provision for uncollectible accounts is recorded as a bad debt expense and included in general and administrative expenses. Account balances are written-off against the allowance when it is probable that the receivable will not
Inventory, Policy [Policy Text Block]	Inventory Inventory consists of raw materials, work in progress and finished goods. The Company does not not
Property, Plant and Equipment, Policy [Policy Text Block]	Property and equipment Property and equipment are stated at cost. Property and equipment financed under capital leases are initially recorded at the present value of minimum lease payments at the inception of the lease. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. Property and equipment under capital leases and leasehold improvements are amortized using the straight-line method over the shorter of the lease term or estimated useful life of the asset. Depreciable lives range from three ten three
Revenue Recognition, Policy [Policy Text Block]	Revenue recognition The Company’s revenues include product and service revenues. Product revenue from diagnostic test kit sales and related accessories is recognized at a point in time based upon contractual rates. Service revenue is recorded based upon contractually established billing rates and recognized upon delivery of test results to the customer. See Note 2 As of December 31, 2018, $9.2 December 31, 2018, no no December 31, 2018. one Revenue expected to be recognized in any future year related to remaining performance obligations is not Taxes assessed by governmental authorities on revenue, including sales and value added taxes, are recorded on a net basis (excluded from revenue) in the consolidated statements of operations.
Cost of Sales, Policy [Policy Text Block]	Cost of revenue: cost of product and cost of service Cost of product revenue consists primarily of costs incurred in the production process, including costs of raw materials and components, assembly labor and overhead, quality management, royalties paid under licensing agreements and packaging and delivery costs. Cost of service revenue consists primarily of costs incurred in the operation of the Company’s diagnostic laboratory including labor and overhead, kit costs, quality management, consumables used in the testing process and packaging and delivery costs.
Cost of Goods and Severice Sold, Shipping and Handling, Policy [Policy Text Block]	Shipping and handling The Company generally bills product customers for shipping and handling and records the customer payments as product revenue. The associated costs are recorded as cost of product sold. The Company does not
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment of long-lived assets The Company’s long-lived assets, including fixed assets and intangible assets which have a definite life, are evaluated for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may may
Business Combinations Policy [Policy Text Block]	Business combinations For acquisitions meeting the definition of a business combination, the Company allocates the purchase price, including any contingent consideration, to the assets acquired and the liabilities assumed at their estimated fair values as of the date of the acquisition with any excess of the purchase price paid over the estimated fair value of net assets acquired recorded as goodwill. When determining the fair value of tangible assets acquired, the Company estimates the cost using the most appropriate valuation method with assistance from independent third third
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]	Goodwill and indefinite-lived intangible assets Goodwill Goodwill is not fourth may no two first not 50% first not not may not Indefinite-lived intangible assets Indefinite-lived intangible assets are reviewed for impairment at least annually, or when events or changes in the business environment indicate the carrying value may first not 50% first not not may not The determinations as to whether, and, if so, the extent to which, indefinite-lived intangible assets become impaired are highly judgmental and based on significant assumptions regarding the projected future financial condition and operating results, changes in the manner of the use and development of the acquired assets, the Company’s overall business strategy, and regulatory, market and economic environment and trends.
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	Definite-lived intangible assets Intangible assets include technology licenses which are capitalized and amortized over estimated useful lives (generally in the range of five twenty
Derivatives, Policy [Policy Text Block]	Derivative financial instruments The Company does not The Company reviews the terms of the shares it issues to determine whether there are embedded derivative instruments, including embedded conversion options, which are required to be bifurcated and accounted for separately as derivative financial instruments. In circumstances where the host instrument contains more than one Bifurcated embedded derivatives are initially recorded at fair value and are then revalued at each reporting date with changes in the fair value reported as other income or expense. When equity instruments contain embedded derivative instruments that are to be bifurcated and accounted for as liabilities, the total proceeds received are first
Fair Value Measurement, Policy [Policy Text Block]	Fair value of financial instruments The Company measures certain financial assets and liabilities at fair value based on the price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants. As of December 31, 2018 2017, 3. Fair value measurement
Research and Development Expense, Policy [Policy Text Block]	Research and development expenses Research and development expenses include all costs associated with the development of the Company’s technology platforms and potential future products including new diagnostic tests that utilize the Company’s technology platforms and are charged to expense as incurred. Research and development expenses include direct costs and an allocation of indirect costs, including amortization, depreciation, rent, supplies, insurance and repairs and maintenance.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Share-based compensation The Company accounts for share-based compensation arrangements with employees, officers and directors by recognizing compensation expense based on the grant date fair value of share-based transactions in the consolidated financial statements. Share-based compensation for options is based on the fair value of the underlying option calculated using the Black-Scholes option-pricing model on the date of grant for share options and recognized as expense on a straight-line basis over the requisite service period. Determining the appropriate fair value model and related assumptions requires judgment, including estimating share price volatility, expected term and forfeiture rates. The expected volatility rates are estimated based on the Company’s actual volatility and the actual volatility of comparable public companies over a historical period equal in length to the expected term. The expected terms represent the average time that options are expected to be outstanding based on the midpoint between the vesting date and the end of the contractual term of the award. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The Company has not not Certain employees have been granted restricted share units, or RSUs, and restricted shares. The fair value of RSUs and restricted shares are calculated based on the closing sale price of the Company’s ordinary shares on the date of grant. The cumulative expense recognized for share-based transactions at each reporting date until the vesting date reflects the extent to which the vesting period has expired and the Company’s best estimate of the number of equity instruments that will ultimately vest. The charge or credit for a period represents the movement in cumulative expense recognized as of the beginning and end of that period. No not Where the terms of an equity award are modified, the minimum expense recognized is the expense as if the terms had not Where a share-based compensation award is cancelled, it is treated as if it had vested on the date of cancellation, and any expense not Upon exercise, share options are redeemed for newly issued ordinary shares.
Income Tax, Policy [Policy Text Block]	Income taxes The Company accounts for income taxes under the asset and liability method, which requires, among other things, that deferred income taxes be provided for temporary differences between the tax basis of the Company’s assets and liabilities and its financial statement reported amounts. In addition, deferred tax assets are recorded for the future benefit of utilizing net operating losses and research and development credit carryforwards. A valuation allowance is established when necessary to reduce deferred tax assets to the amount expected to be realized. The Company adheres to the accounting guidance for uncertainties in income taxes, which prescribes a recognition threshold and measurement process for recording in the financial statements uncertain tax positions taken, or expected to be taken, in a tax return. The Company accrues for the estimated amount of taxes for uncertain tax positions if it is more likely than not not 50%
Earnings Per Share, Policy [Policy Text Block]	Basic and diluted net income (loss) per ordinary share Basic income (loss) per ordinary share are calculated by dividing the net income (loss) by the weighted-average number of ordinary shares outstanding during the period. Diluted income per ordinary share is calculated by dividing net income by the weighted-average number of ordinary shares outstanding during the period plus the dilutive effect of outstanding instruments such as share options, RSUs and restricted shares. Diluted loss per ordinary share is the same as basic loss per ordinary share, as the effect of utilizing the fully diluted share count including share options, RSUs and restricted shares would reduce the net loss per ordinary share.
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Adopted Accounting Pronouncements In May 2014, 2014 09, Revenue from Contracts with Customers 2014 09, 2014 09, 2014 09 2014 09 January 1, 2018, 2014 09 not December 31, 2018. 2014 09 2. Revenue In August 2016, 2016 15, Classification of Certain Cash Receipts and Cash Payments 2016 15. 2016 15 2016 15 January 1, 2018. 2016 15 not In October 2016, 2016 16, Income Taxes 2016 16. 2016 16 January 1, 2018. 2016 16 not In November 2016, 2016 18, Statement of Cash Flows (Topic 230 2016 18. 2016 18 2016 18 January 1, 2018. 2016 18 not In January 2017, 2017 01, Business Combinations 2017 01. 2017 01 2017 01 January 1, 2018. 2017 01 not In May 2017, 2017 09, Scope of Modification Accounting 2017 09. 2017 09 2017 09 January 1, 2018. 2017 09 not Recently Issued Accounting Pronouncements In February 2016, 2016 02, Leases 2016 02. 2016 02 12 2016 02 2016 02, January 1, 2019 2016 02, 12 not 2016 02, $7.7 $8.6 no first 2019, In June 2016, 2016 13, Financial Instruments-Credit Losses 2016 13. 2016 13 2016 13, December 15, 2019. December 15, 2018. not 2016 13 In January 2017, 2017 04, Intangibles – Goodwill and Other 2017 04. 2017 04 2 2017 04 December 15, 2019. 2017 04. In June 2018, 2018 07, Improvements to Nonemployee Share-Based Payment Accounting 2018 07. 2018 07 2018 07 December 15, 2018, 2018 07.

Note 1 - Description of Busin_2

Note 1 - Description of Business and Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Table Text Block]	Year ended December 31, (in thousands) 2018 2017 2016 Cash and cash equivalents $ 192,844 $ 90,332 $ 59,110 Restricted cash, non-current 100 200 200 Total cash, cash equivalents, and restricted cash shown in the statement of cash flows $ 192,944 $ 90,532 $ 59,310

Note 2 - Revenue (Tables)

Note 2 - Revenue (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Disaggregation of Revenue [Table Text Block]	Year ended December 31, (in thousands) 2018 2017 2016 Revenue Product $ 54,687 $ 48,899 $ 43,070 Service 5,066 5,834 3,918 Total revenue $ 59,753 $ 54,733 $ 46,988 Year ended December 31, (in thousands, except percentages) 2018 2017 2016 Revenue United States $ 16,442 28 % $ 15,720 29 % $ 10,372 22 % Europe and ROW 9,153 15 % 8,136 15 % 6,988 15 % Asia 34,158 57 % 30,877 56 % 29,628 63 % Total revenue $ 59,753 100 % $ 54,733 100 % $ 46,988 100 %

Note 4 - Accounts Receivable,_2

Note 4 - Accounts Receivable, Net (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]	December 31, (in thousands) 2018 2017 Accounts receivable $ 9,246 $ 6,021 Less allowance for uncollectible accounts receivable (88 ) — Accounts receivable, net $ 9,158 $ 6,021
Allowance for Credit Losses on Financing Receivables [Table Text Block]	December 31, (in thousands) 2018 2017 2016 Balance at beginning of period $ — $ — $ — Provision for bad debt expense (88 ) — — Write-off — — — Balance at end of period $ (88 ) $ — $ —

Note 5 - Inventory, Net (Tables

Note 5 - Inventory, Net (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Inventory, Current [Table Text Block]	December 31, (in thousands) 2018 2017 Raw materials $ 6,169 $ 6,927 Work in progress 190 179 Finished goods 1,408 31 Inventory $ 7,767 $ 7,137

Note 6 - Property and Equipme_2

Note 6 - Property and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Property, Plant and Equipment [Table Text Block]	December 31, (in thousands) 2018 2017 Laboratory equipment $ 2,951 $ 2,493 Leasehold improvements 5,663 2,766 Office equipment, furniture and fixtures 3,019 2,205 Software 1,626 756 Construction in progress — 94 Property and equipment 13,259 8,314 Less accumulated depreciation (6,115 ) (5,550 ) Property and equipment, net $ 7,144 $ 2,764

Note 7 - Goodwill and Intangi_2

Note 7 - Goodwill and Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]	As of December 31, 2018 Amortization period (years) Gross carrying amount Accumulated Amortization Net carrying amount Licenses 5 - 10 $ 652 $ 591 $ 61 Total $ 652 $ 591 $ 61 As of December 31, 2017 Amortization period (years) Gross carrying amount Accumulated Amortization Net carrying amount Immunetics technology – clinical 15 $ 883 $ 72 $ 811 Immunetics customer relationships 5 - 11 130 14 116 Immunetics trade name 5 30 8 22 Other 5 - 10 692 605 87 Total $ 1,735 $ 699 $ 1,036

Note 8 - Accrued Liabilities (T

Note 8 - Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	December 31, (in thousands) 2018 2017 Employee related expenses $ 5,536 $ 4,317 Corporate tax 1,616 — Royalties 1,354 1,419 Other accrued liabilities 2,385 2,071 Total accrued liabilities $ 10,891 $ 7,807

Note 11 - Share Option and Eq_2

Note 11 - Share Option and Equity Incentive Plans (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	2018 2017 2016 Expected dividend yield (%) — — — Expected volatility (%) 43.70 43.59 43.70 Risk-free interest rate (%) 2.70 1.98 1.53 Expected life of option (years) 6.25 6.20 6.16 Weighted-average share price ($) 13.37 14.06 10.29 Weighted-average exercise price ($) 4.67 14.06 10.29 Model used Black-Scholes Model Black-Scholes Model Black-Scholes Model
Share-based Compensation, Stock Options, Activity [Table Text Block]	Number of ordinary shares WAEP Outstanding as of January 1, 2018 3,104,613 $ 11.62 Granted 796,264 13.37 Exercised (694,322 ) 4.67 Forfeited (643,386 ) 14.31 Outstanding as of December 31, 2018 2,563,169 13.37 Vested or expected to vest as of December 31, 2018 2,494,307 $ 13.37 Exercisable as of December 31, 2018 1,401,639 $ 13.47
Nonvested Restricted Stock Shares Activity [Table Text Block]	Number of ordinary shares WAFV Unvested balance as of January 1, 2018 418,518 $ 14.93 Granted 166,008 13.37 Cancelled (112,694 ) 13.09 Vested (170,878 ) 16.98 Unvested balance as of December 31, 2018 300,954 13.88
Schedule of Nonvested Share Activity [Table Text Block]	Number of shares Weighted- average grant date fair value Balance as of December 31, 2017 1,479,293 $ 5.83 Granted 796,264 6.15 Vested (651,787 ) 5.59 Forfeited (462,240 ) 6.56 Balance as of December 31, 2018 1,161,530 6.06
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	(in thousands) 2018 2017 2016 Cost of revenue $ 182 $ 168 $ 52 Research and development 758 654 497 Sales and marketing 965 1,844 1,671 General and administrative 2,602 3,005 2,681 Total continuing operations 4,507 5,671 4,901 Discontinued operations 1,044 193 118 Total share-based compensation $ 5,551 $ 5,864 $ 5,019

Note 12 - Net Income (Loss) P_2

Note 12 - Net Income (Loss) Per Ordinary Share (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Year ended December 31, ($ in thousands) 2018 2017 2016 Numerator: Income (loss) from continuing operations $ 12,505 $ (33,226 ) $ (21,578 ) Income (loss) from discontinued operations 108,274 341 (771 ) Net income (loss) $ 120,779 $ (32,885 ) $ (22,349 ) Denominator: Weighted-average ordinary shares outstanding-basic 25,982,809 23,757,902 22,353,713 Dilutive effect of ordinary share equivalents resulting from ordinary share options, unvested restricted shares and RSUs 415,066 — — Weighted-average ordinary shares outstanding-diluted 26,397,875 23,757,902 22,353,713
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Year ended December 31, 2018 2017 2016 Options to purchase ordinary shares — 878,242 1,065,655 Unvested restricted shares and RSUs — 418,518 329,465

Note 13 - Income Taxes (Tables)

Note 13 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]	(in thousands) 2018 2017 2016 Domestic (United Kingdom) $ 12,623 $ 18,171 $ (730 ) Foreign (United States) (37,404 ) (49,763 ) (24,622 ) Loss from continuing operations before income taxes $ (24,781 ) $ (31,592 ) $ (25,352 )
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	(in thousands) 2018 2017 2016 Current: Federal $ — $ — $ — U.K. (532 ) — — Japan (45 ) (14 ) (85 ) China (13 ) (39 ) (12 ) State — (46 ) (51 ) Total current provision (590 ) (99 ) (148 ) Deferred: Federal 30,665 — 752 U.K. (1,343 ) (1,535 ) 2,630 State 8,554 — 540 Total deferred benefit (expense) 37,876 (1,535 ) 3,922 Income tax benefit (expense) $ 37,286 $ (1,634 ) $ 3,774
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	2018 2017 2016 Income tax rate 19.0 % 19.3 % 20.0 % U.K. research and development credit 1.8 1.5 1.9 Effect of U.S. tax reform – Federal tax rate change — (69.2 ) — Permanent items 1.0 5.9 (1.9 ) Prior period adjustments (5.2 ) — — State taxes 9.2 9.6 4.9 Other 2.0 4.6 (1.5 ) Effect of foreign tax rate differential 2.9 28.0 13.1 Uncertain tax positions (1.7 ) — — Valuation allowance 121.5 (5.0 ) (21.6 ) Effective income tax rate 150.5 % (5.3 )% 14.9 %
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	(in thousands) 2018 2017 Deferred tax assets: U.S. federal net operating losses $ 11,478 $ 33,713 State net operating loss (net of federal) 2,865 8,450 U.S. federal research and development credit 849 587 U.K. net operating loss 496 1,894 Share options 1,724 2,611 Accrued liabilities 1,052 393 Intangible assets — 2,392 State credits 512 377 Other 136 167 Total deferred tax assets 19,112 50,584 Valuation allowance (17,991 ) (48,098 ) Total deferred tax assets $ 1,121 $ 2,486 Deferred tax liabilities: Other assets $ (69 ) $ — Total deferred tax liabilities $ (69 ) $ —
Summary of Valuation Allowance [Table Text Block]	(in thousands) 2018 2017 2016 Beginning of year (January 1) $ 48,098 $ 46,473 $ 43,076 (Decrease) increase in valuation allowance (30,107 ) 1,625 3,397 End of year (December 31) $ 17,991 $ 48,098 $ 46,473
Summary of Income Tax Contingencies [Table Text Block]	Balance at December 31, 2017 $ — Settlement/decreases related to tax positions taken during prior years — Increases related to tax positions taken during prior years 372 Increases related to tax positions taken during the current year — Balance at December 31, 2018 $ 372

Note 16 - Commitments and Con_2

Note 16 - Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	(in thousands) December 31, 2019 $ 2,024 2020 1,848 2021 972 2022 855 2023 855 Thereafter 7,558 Total minimum lease payments $ 14,112
Schedule of Future Minimum Payments for License Agreements [Table Text Block]	(in thousands) License agreements Supplier purchase obligations Total 2019 $ 262 $ 8,723 $ 8,985 2020 134 — 134 2021 59 — 59 2022 59 — 59 2023 59 — 59 Thereafter 695 — 695 Total minimum payments $ 1,268 $ 8,723 $ 9,991

Note 17 - Geographic Revenue _2

Note 17 - Geographic Revenue and Long-lived Assets Distribution (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]	Revenue Long-lived assets Years ended December 31, As of December 31, (in thousands) 2018 2017 2016 2018 2017 United States $ 16,442 $ 15,720 $ 10,372 $ 1,685 $ 1,071 United Kingdom 3,626 3,041 2,620 5,248 1,487 Europe and ROW (excluding United Kingdom) 5,527 5,095 4,368 101 132 Europe and ROW 9,153 8,136 6,988 5,349 1,619 Asia 34,158 30,877 29,628 110 74 Total $ 59,753 $ 54,733 $ 46,988 $ 7,144 $ 2,764

Note 18 - Acquisition Activity

Note 18 - Acquisition Activity (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	Assets acquired: Property and equipment $ 655 In-process research and development 9,200 Technology - clinical 5,100 Customer relationships 2,700 Trademarks / trade names 1,900 Total assets acquired 19,555 Add: Goodwill 2,645 Total consideration transferred $ 22,200 Assets acquired: Cash $ 285 Accounts receivable, net 347 Inventory, net 375 Prepaid expenses and other assets 199 Property and equipment 787 In-process research and development 6,970 Customer relationships 350 Trade name 160 Technology – clinical 883 Grants 50 Total assets acquired 10,406 Liabilities assumed: Accounts payable (319 ) Accrued liabilities (739 ) Other liabilities (1,226 ) Total liabilities assumed (2,284 ) Net assets acquired 8,122 Add: Goodwill 1,322 Total consideration transferred $ 9,444
Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]	Cash consideration $ 6,000 Estimated fair value of contingent consideration 3,444 Total consideration transferred $ 9,444

Note 19 - Discontinued Operat_2

Note 19 - Discontinued Operations (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Disposal Groups, Including Discontinued Operations [Table Text Block]	December 31, (in thousands) 2017 Carrying amounts of major classes of assets included as part of discontinued operations: Accounts receivable, net $ 10,961 Inventory, net 3,005 Prepaid expenses and other assets 315 Total major classes of current assets of the discontinued operations 14,281 Property and equipment, net 6,303 Goodwill 1,484 Other intangible assets, net 6,813 Other assets 185 Total major classes of noncurrent assets of the discontinued operations 14,785 Total assets of the disposal group classified as assets of discontinued operations in the consolidated balance sheets $ 29,066 Carrying amounts of major classes of liabilities included as part of discontinued operations: Current liabilities: Accounts payable $ 1,290 Accrued liabilities 3,326 Other liabilities 14 Total major classes of current liabilities of the discontinued operations 4,630 Total major classes of noncurrent liabilities of the discontinued operations 48 Total liabilities of the disposal group classified as liabilities of discontinued operations in the consolidated balance sheets $ 4,678 Year Ended December 31, (in thousands) 2018 2017 2016 Major classes of line items constituting income (loss) from discontinued operations before income taxes: Service revenue $ 53,325 $ 56,700 $ 45,705 Cost of service revenue 34,662 36,613 29,596 Gross profit 18,663 20,087 16,109 Research and development 5,751 5,866 4,542 Sales and marketing 7,592 8,963 8,106 General and administrative 3,593 4,917 4,232 Income (loss) from discontinued operations before income taxes 1,727 341 (771 ) Gain on disposition 145,982 — — Income tax expense (39,435 ) — — Income (loss) from discontinued operations $ 108,274 $ 341 $ (771 )

Note 20 - Restructuring (Tables

Note 20 - Restructuring (Tables)	12 Months Ended
	Dec. 31, 2018
Notes Tables
Restructuring and Related Costs [Table Text Block]	(in thousands) Severance Balance at December 31, 2016 $ — Charge for restructuring 182 Payments during 2017 (108 ) Balance at December 31, 2017 74 Payments during 2018 (70 ) Balance at December 31, 2018 $ 4

Note 1 - Description of Busin_3

Note 1 - Description of Business and Significant Accounting Policies (Details Textual)	Nov. 06, 2018USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)
Entity Number of Employees	210
Number of Continents	3
Number of Operating Segments		1
Accounts Receivable Related to Products and Service		$ 9,200,000
Payments of Dividends, Total		$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate		0.00%
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total		$ 37,000	$ 0
Accounting Standards Update 2016-02 [Member]
Operating Lease, Liability, Total		8,600,000
Operating Lease, Right-of-Use Asset		$ 7,700,000
Minimum [Member]
Finite-Lived Intangible Asset, Useful Life		5 years
Maximum [Member]
Finite-Lived Intangible Asset, Useful Life		20 years
Laboratory Equipment, Office Equipment and Furniture And Fixtures [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life		3 years
Laboratory Equipment, Office Equipment and Furniture And Fixtures [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life		10 years
Software Development [Member]
Property, Plant and Equipment, Useful Life		3 years
Customer Concentration Risk [Member] | Sales Revenue, Net [Member]
Number of Major Customers		2
Customer Concentration Risk [Member] | Sales Revenue, Net [Member] | Shanghai Fosun Long March Medical Science Co. Ltd. [Member]
Concentration Risk, Percentage		27.00%
Customer Concentration Risk [Member] | Sales Revenue, Net [Member] | Riken Genesis Co., Ltd. [Member]
Concentration Risk, Percentage		19.00%
Quest [Member]
Proceeds from Divestiture of Businesses	$ 170,000,000

Note 1 - Description of Busin_4

Note 1 - Description of Business and Significant Accounting Policies - Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Cash and cash equivalents	$ 192,844	$ 90,332	$ 59,110
Restricted cash, non-current	100	200	200
Total cash, cash equivalents, and restricted cash shown in the statement of cash flows	$ 192,944	$ 90,532	$ 59,310	$ 83,795

Note 2 - Revenue - Disaggregati

Note 2 - Revenue - Disaggregation of Revenues (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Revenue	$ 59,753	$ 54,733	$ 46,988
Revenue	100.00%	100.00%	100.00%
UNITED STATES
Revenue	$ 16,442	$ 15,720	$ 10,372
Revenue	28.00%	29.00%	22.00%
Europe and ROW [Member]
Revenue	$ 9,153	$ 8,136	$ 6,988
Revenue	15.00%	15.00%	15.00%
Asia [Member]
Revenue	$ 34,158	$ 30,877	$ 29,628
Revenue	57.00%	56.00%	63.00%
Product [Member]
Revenue	$ 54,687	$ 48,899	$ 43,070
Service [Member]
Revenue	$ 5,066	$ 5,834	$ 3,918

Note 3 - Fair Value Measureme_2

Note 3 - Fair Value Measurement (Details Textual) - MidCap Agreement [Member] - MidCap Financial [Member] - USD ($) $ in Millions	Nov. 06, 2018	Sep. 25, 2018
Extinguishment of Debt, Amount	$ 32.3	$ 32.3
Debt Instrument, Prepayment and Exit Fees	$ 2.3	$ 2.3

Note 4 - Accounts Receivable,_3

Note 4 - Accounts Receivable, Net - Summary of Accounts Receivable, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Accounts receivable	$ 9,246	$ 6,021
Less allowance for uncollectible accounts receivable	(88)
Accounts receivable, net	$ 9,158	$ 6,021

Note 4 - Accounts Receivable,_4

Note 4 - Accounts Receivable, Net - Activity for the Allowance for Uncollectible Accounts Receivable (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Balance at beginning of period
Provision for bad debt expense	(88)
Write-off
Balance at end of period	$ (88)

Note 5 - Inventory, Net - Summa

Note 5 - Inventory, Net - Summary of Inventory, Net (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Raw materials	$ 6,169	$ 6,927
Work in progress	190	179
Finished goods	1,408	31
Inventory	$ 7,767	$ 7,137

Note 6 - Property and Equipme_3

Note 6 - Property and Equipment, Net (Details Textual) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Depreciation, Total	$ 1.6	$ 1.4	$ 0.9
Laboratory Equipment, Office Equipment and Furniture And Fixtures [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life	3 years
Laboratory Equipment, Office Equipment and Furniture And Fixtures [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life	10 years
Software Development [Member]
Property, Plant and Equipment, Useful Life	3 years
Specialized Shipping Containers [Member]
Property, Plant and Equipment, Useful Life	3 years

Note 6 - Property and Equipme_4

Note 6 - Property and Equipment, Net - Summary of Property and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Property and equipment, gross	$ 13,259	$ 8,314
Less accumulated depreciation	(6,115)	(5,550)
Property and equipment, net	7,144	2,764
Laboratory Equipment [Member]
Property and equipment, gross	2,951	2,493
Leasehold Improvements [Member]
Property and equipment, gross	5,663	2,766
Office Equipment Furniture and Fixtures [Member]
Property and equipment, gross	3,019	2,205
Software and Software Development Costs [Member]
Property and equipment, gross	1,626	756
Construction in Progress [Member]
Property and equipment, gross		$ 94

Note 7 - Goodwill and Intangi_3

Note 7 - Goodwill and Intangible Assets (Details Textual)	Nov. 06, 2018USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Sep. 30, 2017USD ($)	Jun. 30, 2017USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Sep. 30, 2018USD ($)	Oct. 12, 2016USD ($)
Number of Reporting Units							1
Disposal Group, Including Discontinued Operation, Goodwill										$ 1,500,000
Goodwill, Ending Balance		$ 2,483,000	$ 2,483,000				$ 2,483,000	$ 2,483,000
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life							9 years 255 days
Amortization of Intangible Assets, Total							$ 93,000	206,000	$ 71,000
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months		22,000					22,000
Finite-Lived Intangible Assets, Amortization Expense, Year Three		17,000					17,000
Impairment of Intangible Assets (Excluding Goodwill), Total			7,200,000				879,000	$ 18,300,000	$ 1,765,000
Goodwill, Impairment Loss		0
Finite-Lived Intangible Assets, Amortization Expense, Year Two		22,000					22,000
Quest [Member]
Proceeds from Divestiture of Businesses	$ 170,000,000
Customer Relationships [Member]
Impairment of Intangible Assets (Excluding Goodwill), Total				$ 1,100,000
Trade Names [Member]
Impairment of Intangible Assets (Excluding Goodwill), Total				701,000
In Process Research and Development Member 1 [Member]
Impairment of Intangible Assets (Excluding Goodwill), Total				9,200,000
Immunetics Intangibles [Member]
Impairment of Intangible Assets, Finite-lived		$ 879,000
Immunetics [Member]
Goodwill, Ending Balance											$ 1,322,000
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Inventory					$ (45,000)
Goodwill, Purchase Accounting Adjustments					22,500
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustments Related to Current Period, Income Tax Expense					58,000
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustments Related to Current Period, Cost of Product Revenue					(44,000)
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustments Related to Current Period, Sales and Marketing Expense					(26,000)
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)						$ 1,400,000
Impairment of Intangible Assets (Excluding Goodwill), Total				$ 11,100,000
Goodwill, Impairment Loss							$ 0
Immunetics [Member] | Customer Relationships [Member]
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles					(50,000)
Impairment of Intangible Assets (Excluding Goodwill), Total			98,000
Immunetics [Member] | Trade Names [Member]
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles					(130,000)
Impairment of Intangible Assets (Excluding Goodwill), Total			166,000
Immunetics [Member] | Technology-Based Intangible Assets [Member]
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles					$ 22,500
Immunetics [Member] | In Process Research and Development [Member]
Impairment of Intangible Assets (Excluding Goodwill), Total			$ 7,000,000

Note 7 - Goodwill and Acquired

Note 7 - Goodwill and Acquired Intangible Assets - Acquired Intangible Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Accumulated Amortization, Finite-Lived Intangible Assets		$ 699
Other intangible assets, net	$ 61	1,036
Net Carrying Amount, Finite-Lived Intangible Assets	$ 61	1,036
Gross Carrying Amount, Total		1,735
Net Carrying Amount, Total		1,036
Minimum [Member]
Amortization Period, Finite-Lived Intangible Assets (Year)	5 years
Maximum [Member]
Amortization Period, Finite-Lived Intangible Assets (Year)	20 years
Other Intangible Assets [Member]
Gross Carrying Amount, Finite-Lived Intangible Assets	$ 652	692
Accumulated Amortization, Finite-Lived Intangible Assets	591	605
Other intangible assets, net	61	87
Net Carrying Amount, Finite-Lived Intangible Assets	$ 61	$ 87
Other Intangible Assets [Member] | Minimum [Member]
Amortization Period, Finite-Lived Intangible Assets (Year)	5 years	5 years
Other Intangible Assets [Member] | Maximum [Member]
Amortization Period, Finite-Lived Intangible Assets (Year)	10 years	10 years
Technology-Based Intangible Assets [Member]
Gross Carrying Amount, Finite-Lived Intangible Assets	$ 652
Accumulated Amortization, Finite-Lived Intangible Assets	591
Other intangible assets, net	61
Net Carrying Amount, Finite-Lived Intangible Assets	$ 61
Technology-Based Intangible Assets [Member] | Immunetics [Member]
Amortization Period, Finite-Lived Intangible Assets (Year)		15 years
Gross Carrying Amount, Finite-Lived Intangible Assets		$ 883
Accumulated Amortization, Finite-Lived Intangible Assets		72
Other intangible assets, net		811
Net Carrying Amount, Finite-Lived Intangible Assets		811
Customer Relationships [Member] | Immunetics [Member]
Gross Carrying Amount, Finite-Lived Intangible Assets		130
Accumulated Amortization, Finite-Lived Intangible Assets		14
Other intangible assets, net		116
Net Carrying Amount, Finite-Lived Intangible Assets		$ 116
Customer Relationships [Member] | Minimum [Member] | Immunetics [Member]
Amortization Period, Finite-Lived Intangible Assets (Year)		5 years
Customer Relationships [Member] | Maximum [Member] | Immunetics [Member]
Amortization Period, Finite-Lived Intangible Assets (Year)		11 years
Trade Names [Member] | Immunetics [Member]
Amortization Period, Finite-Lived Intangible Assets (Year)		5 years
Gross Carrying Amount, Finite-Lived Intangible Assets		$ 30
Accumulated Amortization, Finite-Lived Intangible Assets		8
Other intangible assets, net		22
Net Carrying Amount, Finite-Lived Intangible Assets		$ 22

Note 8 - Accrued Liabilities -

Note 8 - Accrued Liabilities - Summary of Accrued Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
Employee related expenses	$ 5,536	$ 4,317
Corporate tax	1,616
Royalties	1,354	1,419
Other accrued liabilities	2,385	2,071
Total accrued liabilities	$ 10,891	$ 7,807

Note 9 - Loans Payable (Details

Note 9 - Loans Payable (Details Textual)	Nov. 06, 2018USD ($)	Sep. 25, 2018USD ($)	Oct. 24, 2016	Oct. 04, 2016USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Jun. 30, 2013USD ($)ft²
Cost to Build Facility, Percentage								80.00%
Loans Payable, Current, Total					$ 85,000	$ 78,000
Loans Payable, Noncurrent, Total					106,000	29,856,000
Gain (Loss) on Extinguishment of Debt, Total					(2,105,000)
MidCap Agreement [Member] | MidCap Financial [Member]
Debt Agreement, Maximum Borrowing Capacity				$ 40,000,000
Debt Agreement, Maximum Borrowing Capacity, Including Additional Increase				60,000,000
Debt Agreement, Final Commitment Fee Percentage			6.00%
Payments for Loans	$ 32,300,000
Debt Instrument, Prepayment and Exit Fees	2,300,000	$ 2,300,000
Gain (Loss) on Extinguishment of Debt, Total	$ (2,100,000)
MidCap Agreement [Member] | MidCap Financial [Member] | Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity				$ 10,000,000
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage				0.50%
Line of Credit Facility, Early Termination, Commitment Fee Percentage, First Year				3.00%
Line of Credit Facility, Early Termination, Commitment Fee Percentage, Second Year				2.00%
Line of Credit Facility, Early Termination, Commitment Fee Percentage, Third Year and Thereafter				1.00%
MidCap Agreement [Member] | MidCap Financial [Member] | London Interbank Offered Rate (LIBOR) [Member] | Revolving Credit Facility [Member]
Debt Instrument, Basis Spread on Variable Rate				4.45%
MidCap Agreement [Member] | MidCap Financial [Member] | Term Loan [Member]
Long-term Debt, Total				$ 30,000,000		30,000,000
Debt Instrument, Term				5 years
Debt Instrument, Periodic Payment, Term				2 years
Debt Instrument, Periodic Payment, Term, Potential Extension				4 years
Debt Agreement, Additional Increase				$ 10,000,000
Debt Agreement, Exit Fee, Percentage			6.00%
MidCap Agreement [Member] | MidCap Financial [Member] | Term Loan [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument, Basis Spread on Variable Rate				7.60%
Lease Incentive [Member]
Loans Payable, Current, Total					84,000	77,000
Loans Payable, Noncurrent, Total					$ 75,000	$ 159,000
Marlborough, Massachusetts [Member]
Area of Real Estate Property | ft²								14,500
Incentive from Lessor								$ 582,000

Note 10 - Share Capital (Detail

Note 10 - Share Capital (Details Textual) $ / shares in Units, $ in Thousands	Aug. 14, 2017USD ($)shares	Dec. 31, 2018USD ($)shares	Dec. 31, 2017USD ($)shares	Dec. 31, 2016USD ($)shares	Dec. 31, 2018£ / sharesshares	Dec. 31, 2017£ / sharesshares	Aug. 14, 2017£ / shares	Aug. 14, 2017$ / shares
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period		694,322	500,182	85,943
Stock Issued During Period, Shares, Restricted Stock Award, Gross		83,378	26,021
Common Stock, Shares, Issued, Total					26,439,334	25,661,634
Common Stock, Shares, Outstanding, Ending Balance					26,439,334	25,661,634
Common Stock, Par or Stated Value Per Share | £ / shares					£ 0.006705	£ 0.006705
Proceeds from Issuance of Common Stock | $			$ 39,298
Common Stock, Shares Authorized					38,978,604	36,183,293
Underwriters [Member]
Stock Issued During Period, Shares, New Issues	2,500,000
Common Stock, Par or Stated Value Per Share | £ / shares							£ 0.006705
Shares Issued, Price Per Share | $ / shares								$ 16.05
Proceeds from Issuance of Common Stock | $	$ 39,300

Note 11 - Share Option and Eq_3

Note 11 - Share Option and Equity Incentive Plans (Details Textual) - USD ($)	Sep. 10, 2018	Dec. 31, 2018	Jun. 30, 2018	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2014	Nov. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value				$ 6.15	$ 6.31	$ 4.53
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weight of Peer Group Average Volatility Used to Determine Expected Volatility		50.00%	75.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weight of Average Volatility Used to Determine Expected Volatility		50.00%	25.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Increase (Decrease) in Weighting of Share Price to Determine Expected Volatility Rate				25.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeiture Rate				5.00%	5.00%	5.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value		$ 2,800,000		$ 2,800,000	$ 10,700,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value		2,400,000		$ 2,400,000	$ 8,800,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period				694,322	500,182	85,943
Proceeds from Stock Options Exercised				$ 3,241,000	$ 561,000	$ 76,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value				6,700,000	7,200,000	1,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value				3,700,000	3,100,000	2,900,000
Allocated Share-based Compensation Expense, Total				5,551,000	5,864,000	5,019,000
Employee Stock Option [Member]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total		5,200,000		$ 5,200,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition				2 years 146 days
Share-based Compensation Arrangement by Share-based Payment Award, Accelerated Vesting, Number	120,000
Allocated Share-based Compensation Expense, Total				$ 3,600,000	3,600,000	3,200,000
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Accelerated Vesting, Number	28,100
Restricted Stock and Restricted Stock Units (RSU's) [Member]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total		$ 3,000,000		$ 3,000,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition				2 years 219 days
Unvested Equity Award [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Number of Employees Affected				35
Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Incremental Compensation Cost				$ 0
Restricted Stock and RSUs [Member]
Allocated Share-based Compensation Expense, Total				$ 2,000,000	$ 2,200,000	$ 1,800,000
2013 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized								2,684,563
Share-based Compensation Arrangement by Share-based Payment Award, Automatic Increase, Percentage of Shares Outstanding								4.00%
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant		1,712,132		1,712,132
2013 Plan [Member] | Until Second Aniversary of Vesting Start Date of Employee First Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage							0.00%
2013 Plan [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period				10 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period				4 years
2013 Plan [Member] | Restricted Stock Units (RSUs) [Member] | Second Anniversary of Grant Date [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage				40.00%
2013 Plan [Member] | Restricted Stock Units (RSUs) [Member] | Third Anniversary of Grant Date [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage				30.00%
2013 Plan [Member] | Restricted Stock Units (RSUs) [Member] | Fourth Anniversary of Grant Date [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage				30.00%

Note 11 - Share Option and Eq_4

Note 11 - Share Option and Equity Incentive Plan - Valuation Assumptions, Stock Options (Details) - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Expected dividend yield (%)	0.00%
Weighted-average exercise price ($) (in dollars per share)	$ 13.37
Employee Stock Option [Member]
Expected dividend yield (%)
Expected volatility (%)	43.70%	43.59%	43.70%
Risk-free interest rate (%)	2.70%	1.98%	1.53%
Expected life of option (Year)	6 years 91 days	6 years 73 days	6 years 58 days
Weighted-average share price ($) (in dollars per share)	$ 13.37	$ 14.06	$ 10.29
Weighted-average exercise price ($) (in dollars per share)	$ 4.67	$ 14.06	$ 10.29
Model used	Black-Scholes Model	Black-Scholes Model	Black-Scholes Model

Note 11 - Share Option and Eq_5

Note 11 - Share Option and Equity Incentive Plan - Stock Option Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Number of share options outstanding (in shares)	3,104,613
Number of share options outstanding, weighted average exercise price (in dollars per share)	$ 11.62
Number of share options granted (in shares)	796,264
Weighted-average exercise price ($) (in dollars per share)	$ 13.37
Number of share options exercised (in shares)	(694,322)	(500,182)	(85,943)
Number of share options exercised, weighted average exercise price (in dollars per share)	$ 4.67
Number of share options forfeited (in shares)	(643,386)
Number of share options forfeited, weighted average exercise price (in dollars per share)	$ 14.31
Number of share options oustanding (in shares)	2,563,169	3,104,613
Number of share options oustanding, weighted average exercise price (in dollars per share)	$ 13.37	$ 11.62
Number of share options vested or expected to vest (in shares)	2,494,307
Number of share options vested or expected to vest, weighted average exercise price (in dollars per share)	$ 13.37
Number of share options exercisable (in shares)	1,401,639
Number of share options exercisable, weighted average exercise price (in dollars per share)	$ 13.47

Note 11 - Share Option and Eq_6

Note 11 - Share Option and Equity Incentive Plan - Restricted Stock Unit Activity (Details) - Restricted Stock Units (RSUs) [Member]	12 Months Ended
	Dec. 31, 2018$ / sharesshares
Unvested balance (in shares) | shares	418,518
Unvested balance, weighted average exercise price (in dollars per share) | $ / shares	$ 14.93
Granted (in shares) | shares	166,008
Granted, weighted average exercise price (in dollars per share) | $ / shares	$ 13.37
Cancelled (in shares) | shares	(112,694)
Cancelled, weighted average exercise price (in dollars per share) | $ / shares	$ 13.09
Vested (in shares) | shares	(170,878)
Vested, weighted average exercise price (in dollars per share) | $ / shares	$ 16.98
Unvested balance (in shares) | shares	300,954
Unvested balance, weighted average exercise price (in dollars per share) | $ / shares	$ 13.88

Note 11 - Share Option and Eq_7

Note 11 - Share Option and Equity Incentive Plan - Unvested Share Option Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Number of unvested share options outstanding (in shares)	1,479,293
Number of unvested share options outstanding, weighted-average grant date fair value (in dollars per share)	$ 5.83
Number of share options granted (in shares)	796,264
Number of unvested share options granted, weighted-average grant date fair value (in dollars per share)	$ 6.15	$ 6.31	$ 4.53
Number of unvested share options vested (in shares)	(651,787)
Number of unvested share options vested, weighted-average grant date fair value (in dollars per share)	$ 5.59
Number of unvested share options forfeited (in shares)	(462,240)
Number of unvested share options forfeited, weighted-average grant date fair value (in dollars per share)	$ 6.56
Number of unvested share options outstanding (in shares)	1,161,530	1,479,293
Number of unvested share options outstanding, weighted-average grant date fair value (in dollars per share)	$ 6.06	$ 5.83

Note 11 - Share Option and Eq_8

Note 11 - Share Option and Equity Incentive Plan - Expense Recognized During the Year Related to Share-based Compensation Transactions (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Share-based compensation	$ 5,551	$ 5,864	$ 5,019
Continuing Operations [Member]
Share-based compensation	4,507	5,671	4,901
Discontinued Operations [Member]
Share-based compensation	1,044	193	118
Cost of Revenue [Member]
Share-based compensation	182	168	52
Research and Development Expense [Member]
Share-based compensation	758	654	497
Selling and Marketing Expense [Member]
Share-based compensation	965	1,844	1,671
General and Administrative Expense [Member]
Share-based compensation	$ 2,602	$ 3,005	$ 2,681

Note 12 - Net Loss Per Ordinary

Note 12 - Net Loss Per Ordinary Share - Basic and Diluted Net Loss Per Share (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income (loss) from continuing operations	$ 12,505	$ (33,226)	$ (21,578)
Income (loss) from discontinued operations	108,274	341	(771)
Net income (loss)	$ 120,779	$ (32,885)	$ (22,349)
Weighted-average ordinary shares outstanding-basic (in shares)	25,982,809	23,757,902	22,353,713
Dilutive effect of ordinary share equivalents resulting from ordinary share options, unvested restricted shares and RSUs (in shares)	415,066
Weighted-average ordinary shares outstanding-diluted (in shares)	26,397,875	23,757,902	22,353,713

Note 12 - Net Loss Per Ordina_2

Note 12 - Net Loss Per Ordinary Share - Antidilutive Securities (Details) - shares	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Employee Stock Option [Member]
Antidilutive securities (in shares)		878,242	1,065,655
Restricted Stock and Restricted Stock Units (RSU's) [Member]
Antidilutive securities (in shares)		418,518	329,465

Note 13 - Income Taxes (Details

Note 13 - Income Taxes (Details Textual) - USD ($)	Apr. 01, 2020	Apr. 01, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Discontinued Operation, Tax Effect of Discontinued Operation, Total			$ 39,435,000
Effective UK Corporate Tax Rate		19.00%	19.00%	19.30%	20.00%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent			21.00%	34.00%	34.00%
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent				17.00%
Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability				$ 21,400,000
Deferred Tax Assets, Net of Valuation Allowance, Total			$ 1,121,000	2,486,000
Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense, Total			37,000	0	$ 0
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total			37,000	0
Unrecognized Tax Benefits, Including Penalties and Interest			409,000	0
Research Tax Credit Carryforward [Member]
Income Tax Credits and Adjustments			0
State and Local Jurisdiction [Member]
Operating Loss Carryforwards, Total			$ 50,300,000	$ 154,900,000
Her Majesty's Revenue and Customs (HMRC) [Member]
Effective UK Corporate Tax Rate			19.00%	19.30%	20.00%
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent			121.50%	(5.00%)	(21.60%)
Operating Loss Carryforwards, Total			$ 2,900,000	$ 11,100,000
Deferred Tax Assets, Net of Valuation Allowance, Total			1,100,000
Internal Revenue Service (IRS) [Member]
Operating Loss Carryforwards, Total			$ 54,700,000	$ 160,500,000
Scenario, Forecast [Member]
Effective UK Corporate Tax Rate	17.00%
Earliest Tax Year [Member]
Open Tax Year					2014

Note 13 - Income Taxes - Compon

Note 13 - Income Taxes - Components of Loss Before Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Domestic (United Kingdom)	$ 12,623	$ 18,171	$ (730)
Foreign (United States)	(37,404)	(49,763)	(24,622)
Loss from continuing operations before income taxes	$ (24,781)	$ (31,592)	$ (25,352)

Note 13 - Income Taxes - Comp_2

Note 13 - Income Taxes - Components for the Income Tax (Expense) Benefit (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Current:
Federal
State		(46)	(51)
Total current provision	(590)	(99)	(148)
Deferred:
Federal	30,665		752
U.K.	(1,343)	(1,535)	2,630
State	8,554		540
Total deferred benefit (expense)	37,876	(1,535)	3,922
Income tax benefit (expense)	37,286	(1,634)	3,774
Her Majesty's Revenue and Customs (HMRC) [Member]
Current:
Foreign	(532)
National Tax Agency, Japan [Member]
Current:
Foreign	(45)	(14)	(85)
State Administration of Taxation, China [Member]
Current:
Foreign	$ (13)	$ (39)	$ (12)

Note 13 - Income Taxes - Effect

Note 13 - Income Taxes - Effective Income Tax Rate Reconciliation (Details)	Apr. 01, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Income tax rate	19.00%	19.00%	19.30%	20.00%
Valuation allowance			17.00%
Her Majesty's Revenue and Customs (HMRC) [Member]
Income tax rate		19.00%	19.30%	20.00%
U.K. research and development credit		1.80%	1.50%	1.90%
Effect of U.S. tax reform – Federal tax rate change			(69.20%)
Permanent items		1.00%	5.90%	(1.90%)
Prior period adjustments		(5.20%)
State taxes		9.20%	9.60%	4.90%
Other		2.00%	4.60%	(1.50%)
Effect of foreign tax rate differential		2.90%	28.00%	13.10%
Uncertain tax positions		(1.70%)
Valuation allowance		121.50%	(5.00%)	(21.60%)
Effective income tax rate		150.50%	(5.30%)	14.90%

Note 13 - Income Taxes - Deferr

Note 13 - Income Taxes - Deferred Tax Assets (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share options	$ 1,724,000	$ 2,611,000
Accrued liabilities	1,052,000	393,000
Intangible assets		2,392,000
State credits	512,000	377,000
Other	136,000	167,000
Total deferred tax assets	19,112,000	50,584,000
Valuation allowance	(17,991,000)	(48,098,000)	$ (46,473,000)	$ (43,076,000)
Total deferred tax assets	1,121,000	2,486,000
Deferred tax liabilities:
Total deferred tax liabilities	(69,000)
State and Local Jurisdiction [Member]
State net operating loss (net of federal)	2,865,000	8,450,000
Internal Revenue Service (IRS) [Member]
U.S. federal net operating losses	11,478,000	33,713,000
U.S. federal research and development credit	849,000	587,000
Her Majesty's Revenue and Customs (HMRC) [Member]
U.K. net operating loss	496,000	$ 1,894,000
Total deferred tax assets	$ 1,100,000

Note 13 - Income Taxes - Defe_2

Note 13 - Income Taxes - Deferred Tax Valuation Allowance (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Beginning of year (January 1)	$ 48,098	$ 46,473	$ 43,076
(Decrease) increase in valuation allowance	(30,107)	1,625	3,397
End of year (December 31)	$ 17,991	$ 48,098	$ 46,473

Note 13 - Income Taxes - Uncert

Note 13 - Income Taxes - Uncertain Tax Positions (Details)	12 Months Ended
	Dec. 31, 2018USD ($)
Balance
Settlement/decreases related to tax positions taken during prior years
Increases related to tax positions taken during prior years	372
Increases related to tax positions taken during the current year
Balance	$ 372

Note 14 - Intellectual Proper_2

Note 14 - Intellectual Property - License Agreements (Details Textual)	12 Months Ended
	Dec. 31, 2018USD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)
Number of License Agreements	3
Royalty Expense	$ 1,100,000	$ 2,800,000	$ 5,200,000
Cost of Goods and Services Sold, Total	$ 16,826,000	$ 18,470,000	$ 16,491,000
Aggregate Royalty Rate, Percent of Gross Product and Service Revenue	2.00%	5.00%	11.00%
License [Member]
Cost of Goods and Services Sold, Total	$ 83,000	$ 80,000	$ 161,000

Note 15 - Employee Benefit Pl_2

Note 15 - Employee Benefit Plans (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Unites States Plan [Member]
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 314,000	$ 277,000	$ 126,000
United Kingdom Plan [Member]
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 685,000	$ 613,000	$ 636,000
Defined Contribution Plan Minimum Annual Contributions per Employee, Percent		5.00%
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay		5.00%

Note 16 - Commitments and Con_3

Note 16 - Commitments and Contingencies (Details Textual)	3 Months Ended	12 Months Ended
	Sep. 30, 2018USD ($)	Dec. 31, 2018USD ($)ft²	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Aug. 31, 2015ft²	Jul. 31, 2015ft²	Mar. 01, 2013
Number of Non-cancelable Operating Leases		7
Lessee, Operating Lease, Renewal Term		2 years
Operating Leases, Rent Expense, Net, Total		$ 2,300,000	$ 1,600,000	$ 1,100,000
Corporate Headquarters [Member]
Lessee, Operating Lease, Term of Contract								5 years
Office Space in Malborough, Massachusetts [Member]
Area of Leased Space | ft²						22,100	7,600
Office Space in Malborough, Massachusetts [Member] | Office Expansion [Member]
Operating Leases, Monthly Rent Expense					$ 12,000
Office Space in Malborough, Massachusetts [Member] | Minimum [Member]
Operating Leases, Monthly Rent Expense					36,000
Office Space in Malborough, Massachusetts [Member] | Maximum [Member]
Operating Leases, Monthly Rent Expense					$ 39,000
Laboratory Space in Memphis, Tennessee [Member]
Lessee Leasing Arrangements, Operating Leases, Optional Extension of Contract		5 years
Quest Sublease [Member]
Operating Leases, Monthly Rent Expense		$ 17,000
Area of Real Estate Property | ft²		9,000
The Abingdon Lease [Member] | Minimum [Member]
Operating Leases, Monthly Rent Expense	$ 39,000
The Abingdon Lease [Member] | Maximum [Member]
Operating Leases, Monthly Rent Expense	$ 79,000

Note 16 - Commitments and Con_4

Note 16 - Commitments and Contingencies - Future Minimum Lease Payments under the Non-cancelable Operating Leases (Details) $ in Thousands	Dec. 31, 2018USD ($)
2019	$ 2,024
2020	1,848
2021	972
2022	855
2023	855
Thereafter	7,558
Total minimum lease payments	$ 14,112

Note 16 - Commitments and Con_5

Note 16 - Commitments and Contingencies - Future Minimum Payments Required Under the License Agreements (Details) $ in Thousands	Dec. 31, 2018USD ($)
License agreements, future minimum payments due in 2019	$ 262
Purchase obligations, future minimum payments due in 2019	8,723
License agreements and purchase obligations, future minimum payments due in 2019	8,985
License agreements, future minimum payments due in 2020	134
Purchase obligations, future minimum payments due in 2020
License agreements and purchase obligations, future minimum payments due in 2020	134
License agreements, future minimum payments due in 2021	59
Purchase obligations, future minimum payments due in 2021
License agreements and purchase obligations, future minimum payments due in 2021	59
License agreements, future minimum payments due in 2022	59
Purchase obligations, future minimum payments due in 2022
License agreements and purchase obligations, future minimum payments due in 2022	59
License agreements, future minimum payments due in 2023	59
Purchase obligations, future minimum payments due in 2023
License agreements and purchase obligations, future minimum payments due in 2023	59
License agreements, future minimum payments due thereafter	695
Purchase obligations, future minimum payments due thereafter
License agreements and purchase obligations, future minimum payments due thereafter	695
License agreements, future minimum payments due	1,268
Purchase obligations, future minimum payments due	8,723
License agreements and purchase obligations, future minimum payments due	$ 9,991

Note 17 - Geographic Revenue _3

Note 17 - Geographic Revenue and Long-lived Assets Distribution (Details Textual)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Number of Geographies in which the Company Operates	3
Geographic Concentration Risk [Member] | Sales Revenue, Net [Member] | CHINA
Concentration Risk, Percentage	48.00%	46.00%	44.00%
Geographic Concentration Risk [Member] | Sales Revenue, Net [Member] | JAPAN
Concentration Risk, Percentage	50.00%	51.00%	55.00%

Note 17 - Geographic Revenue _4

Note 17 - Geographic Revenue and Long-lived Assets Distribution - Revenue and Long-lived Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Revenue by geographic area	$ 59,753	$ 54,733	$ 46,988
Long-lived assets by geographic area	7,144	2,764
UNITED STATES
Revenue by geographic area	16,442	15,720	10,372
Long-lived assets by geographic area	1,685	1,071
UNITED KINGDOM
Revenue by geographic area	3,626	3,041	2,620
Long-lived assets by geographic area	5,248	1,487
Europe and ROW, Excluding U.K. [Member]
Revenue by geographic area	5,527	5,095	4,368
Long-lived assets by geographic area	101	132
European Union [Member]
Revenue by geographic area	9,153	8,136	6,988
Long-lived assets by geographic area	5,349	1,619
Asia [Member]
Revenue by geographic area	34,158	30,877	$ 29,628
Long-lived assets by geographic area	$ 110	$ 74

Note 18 - Acquisition Activit_2

Note 18 - Acquisition Activity (Details Textual)	Oct. 12, 2016USD ($)	Jul. 01, 2016USD ($)	Dec. 31, 2018USD ($)	Jun. 30, 2017USD ($)	Dec. 31, 2018USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2017USD ($)
Goodwill, Ending Balance			$ 2,483,000		$ 2,483,000		$ 2,483,000
Goodwill, Impairment Loss			$ 0
Imugen [Member]
Payments to Acquire Businesses, Gross		$ 22,200,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total		18,900,000
Goodwill, Ending Balance		$ 2,645,000
Goodwill, Tax Deduction, Period		15 years
Business Combination, Acquisition Related Costs						$ 475,000
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual						7,000,000
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual						$ 730,000
Imugen [Member] | Technology-Based Intangible Assets [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total		$ 5,100,000
Imugen [Member] | Customer Relationships [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total		$ 2,700,000
Imugen [Member] | Intangible Assets [Member] | Measurement Input, Discount Rate [Member]
Business Combination, Measurement Input		0.22
Immunetics [Member]
Payments to Acquire Businesses, Gross	$ 6,000,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total	8,400,000
Goodwill, Ending Balance	1,322,000
Business Combination, Pro Forma Information, Revenue of Acquiree since Acquisition Date, Actual	392,000
Business Combination, Pro Forma Information, Earnings or Loss of Acquiree since Acquisition Date, Actual	813,000
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	6,000,000
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Inventory				$ (45,000)
Goodwill, Purchase Accounting Adjustments				22,500
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustments Related to Current Period, Income Tax Expense				58,000
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustments Related to Current Period, Cost of Product Revenue				(44,000)
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustments Related to Current Period, Sales and Marketing Expense				(26,000)
Goodwill, Impairment Loss					$ 0
Immunetics [Member] | General and Administrative Expense [Member]
Business Combination, Acquisition Related Costs	655,000
Immunetics [Member] | Technology-Based Intangible Assets [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total	883,000
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles				22,500
Immunetics [Member] | Customer Relationships [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total	350,000
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles				(50,000)
Immunetics [Member] | Trade Names [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill, Total	$ 160,000
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles				$ (130,000)
Immunetics [Member] | Intangible Assets [Member] | Measurement Input, Discount Rate [Member] | Minimum [Member]
Business Combination, Measurement Input	0.216
Immunetics [Member] | Intangible Assets [Member] | Measurement Input, Discount Rate [Member] | Maximum [Member]
Business Combination, Measurement Input	0.602

Note 18 - Acquisition Activit_3

Note 18 - Acquisition Activity - Fair Value of Identified Assets Acquired (Details) - USD ($)	Dec. 31, 2018	Dec. 31, 2017	Oct. 12, 2016	Jul. 01, 2016
Assets acquired:
Goodwill, Ending Balance	$ 2,483,000	$ 2,483,000
Liabilities assumed:
Goodwill, Ending Balance	$ 2,483,000	$ 2,483,000
Imugen [Member]
Assets acquired:
Property and equipment				$ 655,000
Intangible assets				18,900,000
Net assets acquired				19,555,000
Goodwill, Ending Balance				2,645,000
Total consideration transferred				22,200,000
Liabilities assumed:
Net assets acquired				19,555,000
Goodwill, Ending Balance				2,645,000
Total consideration transferred				22,200,000
Imugen [Member] | Technology-Based Intangible Assets [Member]
Assets acquired:
Intangible assets				5,100,000
Imugen [Member] | Customer Relationships [Member]
Assets acquired:
Intangible assets				2,700,000
Imugen [Member] | Trademarks and Trade Names [Member]
Assets acquired:
Intangible assets				1,900,000
Imugen [Member] | In Process Research and Development, Indefinite Lived [Member]
Assets acquired:
Intangible assets				$ 9,200,000
Immunetics [Member]
Assets acquired:
Property and equipment			$ 787,000
Intangible assets			8,400,000
Net assets acquired			8,122,000
Goodwill, Ending Balance			1,322,000
Total consideration transferred			9,444,000
Cash			285,000
Accounts receivable, net			347,000
Inventory, net			375,000
Prepaid expenses and other assets			199,000
Total assets acquired			10,406,000
Liabilities assumed:
Accounts payable			(319,000)
Accrued liabilities			(739,000)
Other liabilities			(1,226,000)
Total liabilities assumed			(2,284,000)
Net assets acquired			8,122,000
Goodwill, Ending Balance			1,322,000
Total consideration transferred			9,444,000
Immunetics [Member] | Technology-Based Intangible Assets [Member]
Assets acquired:
Intangible assets			883,000
Immunetics [Member] | Customer Relationships [Member]
Assets acquired:
Intangible assets			350,000
Immunetics [Member] | Trade Names [Member]
Assets acquired:
Intangible assets			160,000
Immunetics [Member] | Grants [Member]
Assets acquired:
Intangible assets			50,000
Immunetics [Member] | In Process Research and Development, Indefinite Lived [Member]
Assets acquired:
Intangible assets			$ 6,970,000

Note 18 - Acquisition Activit_4

Note 18 - Acquisition Activity - Business Acquisition, Consideration Transferred (Details) - Immunetics [Member]	Oct. 12, 2016USD ($)
Cash consideration	$ 6,000,000
Estimated fair value of contingent consideration	3,444,000
Total consideration transferred	$ 9,444,000

Note 19 - Discontinued Operat_3

Note 19 - Discontinued Operations (Details Textual) - USD ($) $ in Thousands	Nov. 06, 2018	Sep. 25, 2018	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax, Total			$ 145,982
MidCap Agreement [Member] | MidCap Financial [Member]
Extinguishment of Debt, Amount	$ 32,300	$ 32,300
Debt Instrument, Prepayment and Exit Fees	$ 2,300	2,300
Laboratory Services Business [Member]
Proceeds from Divestiture of Businesses		170,000
Disposal Group, Including Discontinued Operation, Consideration		27,900
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax, Total		$ 146,000
Discontinued Operation, Intra-Entity Amounts, Discontinued Operation after Disposal, Revenue			8,000	$ 8,400
Laboratory Services Business [Member] | General and Administrative Expense [Member]
Professional Fees			$ 3,300

Note 19 - Discontinued Operat_4

Note 19 - Discontinued Operations - Major Classes of Assets and Liabilities and the Results of Discontinued Operations (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Accounts receivable, net		$ 10,961
Inventory, net		3,005
Prepaid expenses and other assets		315
Total major classes of current assets of the discontinued operations		14,281
Property and equipment, net		6,303
Goodwill		1,484
Other intangible assets, net		6,813
Other assets		185
Total major classes of noncurrent assets of the discontinued operations		14,785
Total assets of the disposal group classified as assets of discontinued operations in the consolidated balance sheets		29,066
Current liabilities:
Accounts payable		1,290
Accrued liabilities		3,326
Other liabilities		14
Total major classes of current liabilities of the discontinued operations		4,630
Total major classes of noncurrent liabilities of the discontinued operations		48
Total liabilities of the disposal group classified as liabilities of discontinued operations in the consolidated balance sheets		4,678
Major classes of line items constituting income (loss) from discontinued operations before income taxes:
Service revenue	53,325	56,700	$ 45,705
Cost of service revenue	34,662	36,613	29,596
Gross profit	18,663	20,087	16,109
Research and development	5,751	5,866	4,542
Sales and marketing	7,592	8,963	8,106
General and administrative	3,593	4,917	4,232
Income (loss) from discontinued operations before income taxes	1,727	341	(771)
Gain on disposition	145,982
Income tax expense	39,435
Income (loss) from discontinued operations	$ 108,274	$ 341	$ (771)

Note 20 - Restructuring (Detail

Note 20 - Restructuring (Details Textual) - Plan to Terminate Government Grants [Member]	3 Months Ended		12 Months Ended
	Dec. 31, 2017USD ($)	Sep. 30, 2017USD ($)	Dec. 31, 2017USD ($)
Restructuring and Related Cost, Number of Positions Eliminated	15
Restructuring Charges, Total			$ 182,000
Impairment of Long-Lived Assets Held-for-use		$ 28,000
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)		$ 26,000
Research and Development Expense [Member]
Restructuring Charges, Total	$ 169,000
General and Administrative Expense [Member]
Restructuring Charges, Total	$ 13,000

Note 20 - Restructuring - Accru

Note 20 - Restructuring - Accrued Restructuring Costs (Details) - Plan to Terminate Government Grants [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Balance	$ 74
Charge for restructuring		182
Payments	(70)	(108)
Balance	$ 4	$ 74

Note 22 - Litigation Settleme_2

Note 22 - Litigation Settlement Income (Details Textual) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Settlment Income, Nonoperating	$ 27,500		$ 27,500